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Abstract 
Acute lymphoblastic leukemia (ALL) is the most frequent malignancy of childhood. It is 
the principal cause of cancer–related mortality in children due to a persistent group of 
patients who does not respond to standard anti-cancer treatment. Susceptible patients may 
also suffer from number of toxicities associated with intensive chemotherapy treatment. 
Pharmacogenetic studies of our group, showed that particular genetic variants of the 
folate dependent enzymes, particularly, dihydrofolate reductase (DHFR) and thymidylate 
synthase (TS), major targets of methotrexate (MTX), correlate both individually and 
combined with  increased risk of relapse in patients with childhood ALL. Furthermore, 
variations of ATF5 gene involved in asparagine synthetase (ASNS) regulation and of 
ASNS gene were associated with higher risk of ALL relapse or with ASNase related 
toxicity in patients who received E.coli asparaginase (ASNase). The major goal of my 
doctoral research project was to further understand from the functional point of view the 
role of genetic variations underlying therapeutic responses of childhood ALL, by 
focusing on two major components of ALL treatment, MTX and ASNase. 
My specific goal was to analyze associations found in clinical setting using cellular 
proliferation assay in lymphoblastoid cell lines (LCLs, n=93) and xenograft mice model 
of ALL. Genetic variation in TS polymorphism (homozygosity for triple repeat allele, 3R) 
and of DFHR haplotype *1b (defined by particular allelic combination derived from six 
polymorphic sites in the major and minor promoter of DHFR), on MTX sensitivity was 
assessed using cellular proliferation assay. Similar in vitro assay in response to E.coli 
ASNase was used to access the T1562C variation in the ATF5 5’UTR and particular 
haplotypes of ASNS gene (defined by two genetic variation and arbitrarily named 
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haplotype *1).  Xenograft mouse model was used to access the effect of TS 3R3R 
genotype.  
Analysis of additional polymorphisms in ASNS gene revealed diversification of haplotype 
*1 of ASNS gene in 5 subtypes, two polymorphisms (rs10486009 and rs6971012,) 
defining particular subtypes correlated with in vitro sensitivity to ASNase and one of 
them (rs10486009) seems particularly important for reducing sensitivity to ASNase in 
vitro, possibly providing mechanistic explanation for lower sensitivity of haplotype *1 
observed in clinical setting. No association between ATF5 T1562C variation and cellular 
proliferation assay in response to E.coli ASNase was found.   
          We did not observe genotype-related association when in vitro sensitivity to MTX 
in LCLs was analyzed.  In contrast, in vivo results using xenograft mouse model 
demonstrated the relationship between the TS 3R/3R genotype and the resistance to MTX 
treatment in dose-dependent manner. Obtained results provided function explanation for 
the significantly higher risk of relapse seen in 3R/3R ALL patients and suggest that these 
patients might benefit from increase dose of MTX. Through these experiments we also 
showed that xenogeneic mice model can serve as a preclinical tool to explore 
individualized treatment options.  
In conclusion, the knowledge acquired through my doctoral work confirmed 
and/or identified some functional variants in MTX and ASNase action pathway which 
may facilitate dose individualization strategies, allowing for optimal treatment selection 
or tailoring childhood ALL therapy based on individual genetics.  
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                                    Résumé 
La leucémie aiguë lymphoblastique (LAL) est le cancer pédiatrique le plus fréquent. Elle 
est la cause principale de mortalité liée au cancer chez les enfants due à un groupe de 
patient ne répondant pas au traitement. Les patients peuvent aussi souffrir de plusieurs 
toxicités associées à un traitement intensif de chimiothérapie. Les études en 
pharmacogénétique de notre groupe ont montré une corrélation tant individuelle que 
combinée entre les variants génétiques particuliers d’enzymes dépendantes du folate, 
particulièrement la dihydrofolate réductase (DHFR) ainsi que la thymidylate synthase 
(TS), principales cibles du méthotrexate (MTX) et le risque élevé de rechute chez les 
patients atteints de la LAL. En outre, des variations dans le gène ATF5 impliqué dans la 
régulation de l’asparagine synthetase (ASNS) sont associées à un risque plus élevé de 
rechute ou à une toxicité ASNase dépendante chez les patients ayant reçu de 
l’asparaginase d’E.coli (ASNase). Le but principal de mon projet de thèse est de 
comprendre davantage d’un point de vue fonctionnel, le rôle de variations génétiques 
dans la réponse thérapeutique chez les patients atteints de la LAL, en se concentrant sur 
deux composants majeurs du traitement de la LAL soit le MTX ainsi que l’ASNase. 
Mon objectif spécifique était d’analyser une association trouvée dans des paramètres 
cliniques par le biais d’essais de prolifération cellulaire de lignées cellulaires 
lymphoblastoïdes (LCLs, n=93) et d’un modèle murin de xénogreffe de la LAL. Une 
variation génétique dans le polymorphisme TS (homozygosité de l’allèle de la répétition 
triple 3R) ainsi que l’haplotype *1b de DHFR (défini par une combinaison particulière 
d’allèle dérivé de six sites polymorphiques dans le promoteur majeur et mineur de 
DHFR) et de leurs effets sur la sensibilité au MTX ont été évalués par le biais d’essais de 
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prolifération cellulaire. Des essais in vitro similaires sur la réponse à l’ASNase de E. Coli 
ont permis d’évaluer l’effet de la variation T1562C de la région 5’UTR de ATF5 ainsi 
que des haplotypes particuliers du gène ASNS (définis par deux variations génétiques et 
arbitrairement appelés haplotype *1). Le modèle murin de xénogreffe ont été utilisé pour 
évaluer l’effet du génotype 3R3R du gène TS. 
L’analyse de polymorphismes additionnels dans le gène ASNS a révélé une 
diversification de l’haplotype *1 en 5 sous-types définis par deux polymorphismes 
(rs10486009 et rs6971012,) et corrélé avec la sensibilité in vitro à l’ASNase et l’un d’eux 
(rs10486009) semble particulièrement important dans la réduction de la sensibilité in 
vitro à l’ASNase, pouvant expliquer une sensibilité réduite de l’haplotype *1 dans des 
paramètres cliniques. Aucune association entre ATF5 T1562C et des essais de 
prolifération cellulaire en réponse à ASNase de E.Coli n’a été détectée. 
 Nous n’avons pas détecté une association liée au génotype lors d’analyse in vitro 
de sensibilité au MTX. Par contre, des résultats in vivo issus de modèle murin de 
xénogreffe ont montré une relation entre le génotype TS 3R/3R et la résistance de manière 
dose-dépendante au traitement par MTX. Les résultats obtenus ont permis de fournir une 
explication concernant un haut risque significatif de rechute rencontré chez les patients au 
génotype TS 3R/3R et suggèrent que ces patients pourraient recevoir une augmentation de 
leur dose de MTX. À travers ces expériences, nous avons aussi démontré que les modèles 
murins de xénogreffe peuvent servir comme outil préclinique afin d’explorer l’option 
d’un traitement individualisé. 
 En conclusion, la connaissance acquise à travers mon projet de thèse a permis de 
confirmer et/ou d’identifier quelques variants dans la voix d’action du MTX et de 
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l’ASNase qui pourraient faciliter la mise en place de stratégies d’individualisation de la 
dose, permettant la sélection d’un traitement optimum ou moduler la thérapie basé sur la 
génétique individuelle. 
 
Mots clés: Pharmacogénomique, dihydrofolate reductase (DHFR), thymidilate synthase 
(TS), polymorphismes, méthotrexate (MTX), asparaginase (ASNase), asparagine 
synthétase (ASNS), leucémie pédiatrique, modèle animal. 
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Introduction 
 
                                                     Part I                                                                    
                                                                                                              
       
                                                                                                                                                   
Acute lymphoblastic leukaemia:                                                                                          
                                
                                                                                                       
Acute lymphoblastic leukaemia (ALL) is the most common malignancy of childhood and 
the most common cause of cancer related mortality affecting children from 0 to 14 years. 
About approximately 57 000 cases reported worldwide, particularly, 6000 and 2500 new 
ALL cases are diagnosed every year only in the USA and Canada respectively [1-4]. B-
cell precursor ALL is a main morphologic and histological subtype of childhood 
leukemia with approximately 75-80% of cases. It is one of the most common malignant 
disorders of lymphoid progenitor cells in children with peak prevalence of 3-5 years [5-
8]. During last four decades introduction of multi-agent treatment protocols and risk-
guided treatment changed outcome for children with ALL.  Currently, 5-year event-free 
survival (EFS) rates for childhood ALL is more than 80-85% in the developed countries 
[9]. The other two important childhood leukemia include myelogenous leukemia (AML) 
with frequency of 20% to 25% and chronic myelogenous leukemia (CML) which account 
for 5% of leukemia cases [7].  Although ALL occurs in children and adults, children 
showed better prognosis compared to adults [6, 10]. It has been shown that 95% of 
children achieve complete remission after phase of treatment conducted with several 
intensive multi-agent chemotherapy and about 70% are long-term survivors. Nevertheless 
overall relapse rate is still 20% and survival after relapse remains poor [11].                                              
 
 2 
 
Etiology and epidemiology of childhood leukemia:  
 
 
Childhood ALL might arise from interactions between exogenous (e.g. infection, 
environmental exposure) or endogenous exposures (e.g. inflammation, oxidative stress) 
and genetic (inherited) susceptibility increasing the chance of a mutation in relevant 
oncogenes/tumor suppressor genes and chromosome alterations (Figure 1) [3]. There are 
several known risk factors including ionizing radiation and congenital or genetic 
syndromes (such as Down’s, neurofibromatosis, Shwachman syndrome, Bloom's 
syndrome, and ataxia telangiectasia, and Fanconi’s anaemia) which are associated with 
ALL (collectively <5% of ALL) [4, 7, 8]. Children with Down syndrome (trisomy 21) are 
15 times more likely to develop leukemia compared with children without trisomy 21 [4, 
7]. Diet of the mother and child, parental smoking, pesticides and household chemicals, 
traffic fumes are environmental exposures suggested to contribute to ALL development. 
The incidence rate of disease increased by 1% during last two decades. Furthermore, 
immune modulators through for example infections and vaccinations, can as well play a 
role in onset of lymphoblastic leukemia in particular the pre-B cell childhood ALLs [4].  
A large number of risk factors including genetic component of ALL remains still 
undefined. 
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Figure 1: Different causes of childhood ALL (Inaba 2013). 
 
 
 
 
 
 
 
 
 
Figure 2: Morphologic and immunohistochemical (IHC) pictures of B-ALL 
patients: A, The blasts with azurophilic granules. B, Diffuse infiltrate replacing bone 
marrow medullary space.  Wright-Giemsa–stained bone marrow (Zhou 2012). 
 
Endogenous 
Genetic  
Exogenous 
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Genetic alterations in ALL: 
 
Based on evidences commonly mutated genes in ALL patients are those involved in the 
development and differentiation of various types of blood cells, and these genes vary 
according pre-B or T cells leukemia [12]. ALL also has been classified into B-acute 
lymphoblastic leukemia (B-ALL) and T-cell lineage ALL (T-ALL). Furthermore, ALL 
has been traditionally classified into precursor B, B-cell and precursor T (or T-cell) 
phenotypes. According karyotypic abnormalities, ploidy and translocations, they will be 
further subdivided [13]. B-ALL is derived from B-cell progenitors (Figure 2). B-ALL 
accounting for 80%, while T-ALL comprises 12%-15% of all newly diagnosed paediatric 
childhood ALL. T-cell ALL is associated with a poor prognosis with only 7–23% of 
patients surviving for 3 to 5 years [10, 14]. Patients with B-ALL can be classified to 
ETV6-RUNX1 (TEL-AML1) B-ALL, TCF3-PBX1 (E2A-PBX1), BCR–ABL1 ALL, MLL–
rearranged B-ALL according to specific genetic abnormality [15, 16] (Figure 3).  ETV6-
RUNX1 involves ETV6, previously known as TEL, on chromosome 12p13 and RUNX1, 
located on chromosome 21q22, previously known as AML1 which is a transcription 
factor required for hematopoietic development and differentiation in embryonic and adult 
stages. TEL-AML1 translocation occurs in 20% to 25% of childhood ALL cases and 
confers a favorable prognosis [10, 12, 15, 17]. Another most common genetic 
abnormality is t(1;19) (q23;p13) which results in the fusion of the TCF3 (formerly E2A) 
gene with the PBX1 gene which occurs in 3-5% of B-ALL patients and is usually 
associated with favorable outcome, but in adult ALL  the prognosis of t(1;19) patients 
with French and Italian studies reporting poor outcomes [10, 18]. High risk, includes 
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rearrangements of the mixed lineage leukemia (MLL) gene; and very high risk includes 
translocation t(9:22) which generate the BCR-ABL1 fusion gene, known as the 
Philadelphia chromosome, and hypodiploidy [15, 16, 19, 20]. The frequency of 
Philadelphia chromosome is about 3% to 6% among childhood ALL, but occurs more 
frequently (around 25%) among adults [15]. Based on recent studies of genome-wide 
profiling using microarrays, candidate gene, and second-generation sequencing helped to 
identify other genetic alterations that define new ALL subtypes.  Deletion of the IKZF1 
(IKAROS) is common in BCR-ABL1 lymphoid leukemia but is rarely present in CML at 
chronic phase. IKAROS is a zinc finger transcription factor required for the development 
of all lymphoid lineages.  IKZF1 alteration cooperate with BCR-ABL1 in the induction of 
lymphoblastic leukemia and subsequent resistance to therapy in recent experimental 
models of BCR-ABL1 ALL [15]. ALL patients carrier IKZF1 deletion had lower 5 years 
EFS (30%) comparing those without this genotype (51%) and they showed very poor 
outcome in spite of haemopoietic stem-cell transplantation [14]. Deletion in IKZF1 gene 
which involved in regulating B-cell differentiation at relapse, commonly occur in the 
BCR-ABL1-like ALL subtype, BCR-ABL1-like ALL include more than 15% of childhood 
B-ALL cases which exhibit a gene expression profile similar to that of BCR-ABL1–
positive ALL, often have deletion/mutation of IZKF1, and associated with a very poor 
outcome [14, 15].   
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Figure 3. A) Genetic subtypes in childhood B-ALL and B) Distribution of acute 
lymphoblastic leukemia subtypes by age.  (Inaba 2013 and Wiemels 2012). 
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Genetic profile and immunophenotypic features of B-ALL: 
 
To differentiate cancer arises from precursors of B or T cell, the bone marrow smear 
undergoes cytochemical staining for distinguishing between lymphoid and myeloid 
blasts. To further classify the leukemia, the blasts undergo immunophenotypic 
classification that measures the expression of cytoplasmic and surface antigens, which 
can discriminate B-cell, early pre-B-cell, pre-B-cell, or T-cell leukemia [10, 20]. In this 
regard, early pre–B lymphoblasts express CD19 (100% of patients), cytoplasmic CD22, 
and CD34 and later pre–B cells are positive for CD10, CD45 and CD20. Likewise T-cell 
leukemia is positive for CD3, CD5, CD7, CD10 and CD34 [10, 21]. 
 
Ploidy within a leukemia blast cell population: 
 
Determination of the modal number of the leukemia chromosomes is one of the 
prognostic factors for B-cell precursor ALL patients. Chromosome number (ploidy) 
within a leukemia blast cell population includes hyperdiploidy with 51–68 chromosomes, 
low hyperdiploidy with 47-50 chromosomes, pseudodiploidy with 46 chromosomes, 
diploid or  normal with no cytogenetic abnormalities and hypodiploidy with ≤45 
chromosomes which occur respectively  25% to 30%, 11%, 28%, 30% and 7%–8% of 
childhood ALL cases [15, 20, 22]. Hyperdiploid leukemia confers a favourable 
prognosis, but hypodiploid leukemia with a chromosome number less than 46 is 
associated with poor prognosis [15, 20].   
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Molecular Monitoring and Response to Therapy: 
 
 
The significance of the morphological examination is now being replaced by the 
detection of minimal residual disease (MRD), through flow cytometric detection of 
leukemia-associated immunophenotypes or PCR amplification of fusion transcripts, 
immunoglobulin (IG) and T-cell receptor (TCR) gene [23-25]. MRD is the single most 
powerful prognostic marker for patients in all risk groups, which can determine the 
response to treatment in ALL patients more precisely than morphological screening of 
bone marrow smears. Likewise, MRD now become the new definition for leukemia 
remission and is measured concurrently with the morphological examination. The other 
advantages and applications of MRD detection in patients with ALL are determining 
remission status before and after transplantation, and detecting early relapse. 
Accordingly, measuring MRD levels during remission induction therapy provide 
important prognostic information [25]. MRD level inversely correlates with 5 years event 
free survival (EFS) rate. Based on obtained results, the EFS of 88% is correlates to MRD 
level less than 0.01% and, EFS of 59%, 49% and 30% are correlates with MRD level 
more than 0.01%, 0.1%, and 1% respectively. Now, cytogenetic and MRD statuses are 
the 2 most important prognostic factors both in childhood B-ALL and adult B-ALL[10]. 
Based on Dana-Farber Cancer Institute (DFCI) protocol and investigation, end-induction 
MRD level can be considered as a significant independent predictor of outcome [26]. 
According to DFCI treatment protocol, children with high end-induction MRD (≥0.001) 
had a 10.5-fold greater risk of relapse than those with low MRD [26]. Considering MRD 
levels in the BM at day 15 were well correlated with risk of relapse, determining MRD 
levels at day 15 is an informative checkpoint to test the in vivo sensitivity of the leukemia 
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in the individual precursor B-cell ALL [27]. Likewise, patients presenting high levels of 
MRD at day 33 (at the end of induction phase) and no MRD detectable at day 78 (at the 
end of intensification phase) had a favourable outcome, but those with detectable MRD at 
day 78, showed significant increase risk of relapse [28].   
Treatment: 
Treatment of paediatric ALL has greatly improved due to the introduction of effective 
combination risk-adapted therapies. DFCI Consortium treatment protocol and their risk 
group classification for childhood ALL, is one of the referent protocol currently used for 
childhood ALL management and treatment (Table 1, II) [26]. DFCI ALL Consortium has 
been conducting multi institutional clinical trials in the United States and Canada in 
childhood ALL since 1981. DFCI Consortium treatment protocol assigned as a research 
protocols and in term of clinical research always addressing particular research questions 
through randomization. The major goal of DFCI ALL Consortium Protocol 91-01 
conducting randomized clinical trials in childhood ALL and continuing focusing on 
improving efficacy and  outcome of newly diagnosed ALL children while minimizing 
acute and late toxicities [26, 29]. Based on DFCI results, 1457 children aged 0–18 years 
were treated on four consecutive protocols among 1985–2000 [26]. The 2 year DFCI 
treatment program consisted of four phases; multi-agent remission induction therapy (4 
weeks); CNS-directed treatment (3 weeks); intensification (20-30 weeks) and therapy 
will be continued until the completion of 24 months of complete remission [26, 29]. 
Treatment protocols vary based on risk group classification determined at the time of 
diagnosis, include; standard risk (SR), high risk (HR) and very high risk (VHR). CNS 
treatment for SR and HR patients began on the day that complete remission was attained. 
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The goal of remission induction treatment (also called induction therapy) for ALL is to 
restore normal hematopoiesis in 96–99% of children and 78–92% of adults with ALL and 
bring about a complete remission with as few toxic adverse effects as possible [3, 30, 31]. 
The speed rate and depth of the early response to remission induction therapy recognise 
as a major index of subsequent therapy in many protocols worldwide [32]. Remission 
induction is 4 weeks duration phase and patients received a vincristine, corticosteroids 
such as prednisone and dexamethasone, doxorubicin, cytarabin, ASNase and MTX. 
The goal of central nervous system (CNS) directed therapy is critical to maximize and 
improved survival rates. CNS therapy which elongated three weeks includes all remission 
induction phase drugs plus 6-mercaptopurine [26, 33]. CNS treatment for infants was 
delayed until the age of 12 months [33]. Intensification therapy is a critical phase of 
lymphoblastic leukemia treatment protocol to eradicate residual leukaemic cells [3, 26, 
33]. Although about two-thirds of lymphoblastic leukemia cases can be treated 
successfully only with 12 months of treatment. Patients with childhood leukaemia need 
continuation treatment in order to prevent possible relapse [34]. Thus continuation 
therapy is beginning after intensification, and continued until the completion of 24 
months of complete remission [26, 33].  
Drugs used in ALL: 
Protocol phases and related drugs based on risk group presented in table 1 and 2 [26, 33]. 
Cytosine arabinoside (Cytarabine, Ara-C) is an antimetabolite widely used in acute 
leukemia. Cytarabine must be phosphorylated to cytotoxic metabolite Ara-CTP (Ara-C 
three phosphates) and exert its cytotoxicity during or after incorporation into the DNA 
where they interfere with DNA strand elongation, replication, or repair processes [35]. 
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Cytarabine therapy is associated with several adverse side effects, including 
myelosuppression, infections, mucositis, neurotoxicity, and acute pulmonary syndrome 
[36].  
Doxorubicin is an anthracycline antibiotics commonly used in the treatment of 
leukemias. The major doxorubicin related concern is well-known dose-related 
cardiotoxicity [36]. Doxorubicin attack cancer cells by multiple mechanisms; they work 
primarily by DNA intercalation and inhibiting replication which lead to DNA damage 
and cell death. Also doxorubicin binds to mitochondrial DNA, inhibiting other cellular 
functions. It can inhibit the action of topoisomerase II, an enzyme that unzips the DNA 
molecule for replication [37, 38].  
6-Mercaptopurine (6-MP) is an antimetabolite and an analog of purine base.  It is 
important component of ALL treatment administered during intensification and 
maintenance treatment phases. Upon entry into the leukemic cells it is metabolized to 6-
thioguanine nucleotides (6-TGN) by thiopurine methyltransferase (TPMT). 6-MP exerts 
its cytotoxic effect by inhibition of DNA synthesis and by interfering with the activity of 
nucleic acid-processing enzymes. More precisely, TGN incorporation into the DNA and 
RNA results in DNA strand-breaks, chromatid damage and subsequent cell cycle arrest 
and apoptosis. 6-TGN is more potent than 6-MP; based on in vitro and in vivo data, 
lymphoblasts are more sensitive to 6-TGN and exert more toxicity compared to 6-MP.   
6-TGN is no longer used for continuation treatment, because it has been associated with 
thrombocytopenia, an increased risk of death, and hepatic veno-occlusive disease upon 
prolong use of thioguanine at a dose more than 40 mg/m2 [13, 19]. 6-TGN is active 
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metabolite of 6-MP which has cytotoxic and immunosuppressive properties [39, 40].   
TPMT genotyping may be useful to predict this risk prior to drug administration [36, 40].  
Vincristine is important vinca alkaloids known as antimicrotubule agent. The most 
frequent and clinically important side-effect of vincristine is dose-limiting autonomic and 
peripheral sensory-motor neuropathy [36, 41]. Vincristine induces cytotoxicity by 
interacting with and disrupting microtubules polymerization, especially those comprising 
the mitotic spindle apparatus so microtubules do not form. Vincristine also binds to 
neuronal tubulin, lead to disrupting axonal microtubules and causing neurotoxicity [42]. 
Corticosteroids induce apoptosis in the malignant lymphoid cells and are critical 
component of combination therapy for ALL. Glucocorticoids exert their cytotoxicity 
effects by binding with glucocorticoid receptors (GR). After binding, GR can 
homodimerize and translocate to the nucleus, and interact with glucocorticoid response 
elements to transactivate gene expression, resulting expression alteration in various 
oncogenes, cell cycle arrest and apoptosis [43][44]. Dexamethasone and prednisone may 
cause avascular necrosis (AVN) or osteonecrosis as a chronic complication of leukaemia 
treatment [45]. However, dexamethasone has a longer half-life and better central nervous 
system (CNS) penetration, appears to yield better CNS control [43].  
Mechanism of action and pharmacogenomics of MTX and ASNase as two major 
components of DFCI protocol precisely presented in future sections.  
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Table 1:  ALL treatment protocol; DFCI 1985–2000; SR: standard risk, HR: high 
risk, IV: intravenous, IM: intramuscular (Modified from LeClerc. 2002 and 
Silverman 2010). 
Induction 
(4 weeks) 
CNS therapy 
(3 weeks) 
Intensification 
(20–30 weeks) 
Every 3 week 
cycles 
Continuation 
(78 weeks) 
Every 3 week cycles 
prednisone 
daily, 40mg/ m2 
(days 0–28) 
IV (SR) 
Vincristine 
2 mg/m2 IV 
(day 1) (SR) 
Prednisone 
daily 40 mg/m2 
orally days 1–5 
or (SR) 
Dexamethasone 
daily 6 mg/m2 
for 5 days (SR) 
Prednisone 
daily 40mg/ m2 
for 5 days within 
3- weeks cycle (SR) 
or 
Dexamethasone 
6-18 mg/m2 
(SR & HR) 
Vincristine 
1.5 mg/m2 
(days 0, 7, 14, 21) 
IV (SR) 
Hydrocortisone 
9-15 mg 
(SR) 
Doxorubicin 
30 mg/m2 day 1 of 
each cycle (HR) 
Vincristine 
2.0 mg/m2 IV 
day 1 
(SR) 
Cytarabine 
intrathecal 
1 dose according to 
age (day 0) (SR) 
Cytarabine 
intrathecal 
twice weekly × 4 
doses (SR) 
Vincristine 
2.0 mg/m2 IV 
day 1 (SR) 
Methotrexate 
weekly 
30 mg/m2 
(SR) 
Doxorubicin 
30 mg/m2/dose 
(days 0 and 1) 
IV (SR) 
Methotrexate 
intrathecal 
4 doses of 6-12 mg 
 
Methotrexate 
30 mg/m2 IV or IM 
days 1, 8, 15 (SR) 
6-Mercaptopurine 
daily 50 mg/m2 
orally days 1–15 
(SR) 
Methotrexate 
one dose of 4g/ m2 
with leucovorin 
(day 3) 
IV (SR) 
 
6-Mercaptopurine 
daily 50 mg/m2 
orally days 1–15 
(SR) 
Asparaginase 
E.coli ASP 
25,000 IU/m2 
weekly or PEG 
ASP 2500 IU/m2 
every 2-weeks 
(SR) 
 
Asparaginase 
E.coli or Erwinia 
ASP 25,000 IU/m2 
× 1 dose (day 4) 
(SR) 
Doxorubicin 
30 mg/m2 day 1 of 
each cycle (HR) 
6-Mercaptopurine 
daily 50 mg/m2 
orally days 1–15 
for 14 days (SR) 
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Table 2: Risk Group Classification on DFCI ALL Consortium Protocols (1985–2000)  
(Modified from Silverman 2010). 
 
 Standard Risk: 
(All of the following) 
High Risk: 
(Any of the following) 
Very High Risk: 
(Any of the following) 
Age 1985–95: 2 to < 9 years 
1995–2000: 1 to < 10 years 
1985–95: ≥ 9 years 
1995–2000: ≥ 10 years 
1985–2000: < 12 
months 
WBC (× 109/L) 1985–95: < 20 
1995–2000: < 50 
1985–91: 20 to < 
1001991–5: ≥ 20 
1995–2000: ≥ 50 
1985–91: ≥ 100 
Cell type B-precursor T-cell  
Clinical CNS disease Absent Present  
TEL-AML1 (ETV6-
RUNX1) -  t(12:21) 
Present Absent  
Mixed Lineage Leukemia 
(MLL) 
Absent Present  
BCR-ABL1-t(9;22) 
Philadelphia chromosome 
Absent Present  
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Pharmacogenomics and importance of ALL:  
Pharmacogenomics is the study of genetic variation of drug-metabolizing enzymes, 
receptors, transporters and targets, and talk about how these genetic variations (either 
inherited, acquired or both) affects drug-related phenotypes, such as drug response or 
toxicity. The major goal of pharmacogenomics is providing strategies to individualize 
therapy based on human genetic variability and its influence on drug response. Although 
pharmacogenetics and pharmacogenomics terms are often used interchangeably, the 
pharmacogenetics is the study of genetically determined variation in how individuals 
respond to drugs, but pharmacogenomics used to describe the study of the entire 
spectrum of genes that determine drug responses in relation to the diversity of the human 
genome sequence and its clinical consequences [46, 47]. Progress in pharmacogenomics 
studies provide significant potential for further clinical application in order to improve 
clinical outcomes in individual patients [46]. The treatment of paediatric ALL has greatly 
improved due to the introduction of effective combination risk-adapted therapies. 
However, therapy resistance is still a major obstacle to successful treatment, whereas 
intensive treatment has also important short-term side effects and long-term 
consequences. Unfavourable clinical pharmacokinetics and pharmacodynamic as well as 
cellular drug resistance play a major role in ALL treatment failure [48]. In this regard, 
treatment related toxicity is one of the major reasons for withdrawal or discontinuation, 
which might be increase risk of relapse despite of standard treatment approaches. On the 
other hand intensive treatment has short and long term consequences, such as 
myelosuppression, infection, and thrombosis, alteration in glucose metabolism, secondary 
malignancies, growth retardation, bone abnormalities, neurotoxicity or cognitive 
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impairments [36, 49-51]. Then, most important concern of oncologist is to recognize 
ALL patients before relapse due to fail in current treatment protocols [9].  Numerous 
pharmacogenetic studies have shown that polymorphisms in genes that encode drug 
metabolising enzymes and targets can affect enzymatic activity and modulate drug action 
[52]. Drug resistance and drug-related side effects can be due to polymorphisms in genes 
that encode enzymes involved in drug pharmacokinetics and pharmacodynamic. 
Polymorphisms in such genes often referred to as candidate genes are analyzed in 
pharmacogenetic studies for their capability to predict unfavourable treatment responses. 
Identification of such polymorphisms may lead to different treatment schedules, 
improving the efficacy of treatment and allowing for a reduction in drug side effects [50].   
ALL was widely addressed in number of pharmacogenetic studies including candidate 
gene approach and Genome Wide Association Studies (GWAS). These studies increased 
our knowledge on genetic contribution to specific drug metabolism and signalling 
pathways [19]. One of the best examples of pharmacogenomics studies in ALL is 6-MP 
dosing based on TPMT genotypes and subsequent association of dose adjustment with 
better outcomes and less toxicity [19] TPMT enzyme is affected by functional 
polymorphisms which define the most prevalent mutant alleles associated with loss of 
catalytic activity and play an important role in metabolites pharmacokinetics variability 
affecting the balance between 6-MP efficacy and toxicity. These polymorphisms include 
three SNPs in the TPMT gene; TPMT*2 (238G > C), TMPT*3A (G460A), 
and TPMT*3C (719A > G) alleles, which account for 90% of the enzymatic deficiency in 
most populations. Due to higher TGN accumulation these polymorphisms have been 
associated with increased risk of myelosuppression [19, 36, 78] in ALL patients treated 
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with standard 6-MP doses. However in a case of treatment adjusted according to the 
TPMT genotypes. Based on TPMT genotyping, about 90% of the individuals have two 
wild-type TPMT alleles (TPMT*1), thus they have normal enzyme activity whereas 
individuals with two nonfunctional alleles (1 in 300) have very low or lack of TPMT 
activity, resulting high levels of TGN and acute hematopoietic toxic effects. Patients who 
carry two nonfunctional TPMT alleles experience severe myelosuppression, if treated 
with standard doses of thiopurines. These patients require a reduction of more than 90% 
of the standard doses. Likewise administration of 50% of the standard dose is 
recommended for about 5-10% of individuals who carrier heterozygous alleles and have 
intermediate levels of enzyme activity. TPMT-deficient patients, upon thiopurine dose 
adjustment can tolerate full doses of their other ALL chemotherapeutic agents which 
associated with greater therapeutic efficacy [36, 78].In addition to the analysis in clinical 
setting which addresses an association between polymorphisms and therapeutic 
responses, understanding functional effect of identified polymorphism makes also the 
part of pharmacogenetic studies spectrum and may as well give an indication for drug 
dose adjustments. This is of particular interest when treatment in composed of multiple 
therapeutics as in case of ALL.                                          
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                                                  Part II                                                                     
                                                                      
Methotrexate (MTX) as a major anti-neoplastic component in ALL 
treatment protocol:                            
MTX is an important antifolate drug, designed to mimic a folate molecule which bind in 
the active site of folate-dependent enzymes and block its action (Figure 4). MTX is an 
essential drug used in the treatment’s protocol of several malignant and non-malignant 
diseases including ALL, choriocarcinoma, osteogenic sarcoma, seminoma, as well as 
lung, mammary gland and ovarian cancer [53-57]. Apart of antitumor effects, MTX play 
a major role in treatment autoimmune diseases, such as rheumatoid arthritis (RA) and 
moderate to sever psoriasis [58, 59], lupus erythematosis and inflammatory bowel disease 
(IBD) [60] primary billiary cirrhosis and intrinsic asthma, as well as prevention of graft-
versus-host disease (GVHD) [49]. MTX is used in induction, CNS relapse prevention, 
and maintenance therapy in ALL treatment protocol [26, 29]. Also MTX as a broad 
spectrum antitumor component used in treatment’s protocol of several malignancies such 
as accordingly, high-dose MTX (HDMTX) is commonly given in induction phase, and 
low-dose oral MTX (LDMTX) is given in maintenance therapy in ALL treatment’s 
protocols [61-63].  MTX uses the reduced folate carrier 1 (RFC1) or solute carrier family 
19 member 1 (SLC19A1), for entering the cells [28, 36, 50, 57, 64], ABC proteins 
(specifically the ABCC1-4 and breast cancer resistant, ABCG2 proteins) for the transport  
out of the cell (Figure 5) [28, 50, 57, 63]. Overexpression of ABCC2 
[(multidrug resistance-associated protein (MRP) 2] may lead to lower cellular MTX 
accumulation and subsequent moderate to high level of resistance [65, 66].  Impaired 
function of RFC1 has been recognized as a frequent mechanism of anti-folate resistance 
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[49].  Variations in this gene have been also showed to contribute to MTX response. RFC 
gene is located on human chromosome 21, Mostly investigated polymorphism is RFC1 
80G>A. Patients with AA genotype showed higher MTX plasma level of MTX in their 
plasma due to impaired MTX influx [50, 56, 67, 68]. Some of chromosomal 
translocations that are typical for ALL cells may have altered level of MTX influx and 
efflux proteins. For example, E2A-PBX1 ALL patients showed significantly lower 
expression of RFC1 and TEL-AML1 ALL patients showed higher expression of ABCG2. 
Both conditions lead to decrease in MTX polyglutamates (MTXPG) level in the cells and 
subsequent resistance to MTX [56]. The solute carrier organic anion transporter 1B1 
(SLCO1B1), which is mainly expressed in the liver, is important for hepatic uptake and 
thus for the pharmacokinetics of MTX [68].  It has been shown that variants in the 
SLCO1B1 gene are associated with MTX clearance and gastrointestinal (GI) toxicity in 
ALL patients [68]. After entering the cells (especially in hepatocytes, erythrocytes, and 
tumour cells), MTX undergoes polyglutamylation to MTX polyglutamates via 
folylpolyglutamate synthetase (FPGS) (Figure 5).  Polyglutamation increases intracellular 
retention of MTX and subsequent affinity for the MTX-sensitive enzymes within the cell 
[55, 57, 63, 69]. In the other words, MTX gains its antileukemic effects through an 
accumulation of long-chain MTXPG [56, 57, 67]  the level and time-course of MTXPG 
formation in tumour cells is a key determinant of the cytotoxic activity exerted by MTX 
[65].  Pre B-ALL have more efficient accumulation of (long chain) MTXPGs compared 
to T-ALL and acute myeloid leukemia [69]. Reversed process is directly dependant on 
active transport of MTXPG into lysosome and further hydrolysis by γ-glutamyl hydrolase 
(GGH), which allows efflux of the drug out of the cell [50, 55, 57, 68]. Moreover, 
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MTXPG can inhibit glycinamide ribonucleotide transformylase (GARTF) and 
aminoimidazole carboxamide ribonucleotide transformylase (AICART), the two enzymes 
essential for de novo biosynthesis of purines [55, 68]. MTX and MTXPG acts as 
competitive inhibitors of several key enzymes in folate pathway such as dihydrofolate 
reductase (DHFR), thymidylate synthase (TS), 5,10-methylenetetrahydrofolate reductase 
(MTHFR) [28, 36, 64], and enzyme of purine synthesis resulting in DNA synthesis 
impairment and  cell death [50, 55, 67]. In contrast to classic antifolates, nonclassical or 
novel antifolates, defined as antifolates that do not require active transport or 
polyglutamation, can passively diffuse into cells and do not depend on FPGS or the RFC. 
The most important nonclassical antifolates are trimethoprim (TMP), trimetrexate (TMQ) 
and piritrexim (PTX) [70-72].  
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Figure 4: MTX as an important antifolate drug; 
MTX is designed to mimic a folate molecule, binds to the active site of the folate-
dependent enzymes and blocks its action.  Methotrexate has the same size and chemical 
composition as folate molecule. The similar structure of MTX and folate, suggests their 
competitive binding to same molecules (2014 David Goodsell & RCSB Protein Data 
Bank, http://www.rcsb.org/pdb/101/motm.do?momID=34).      
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Figure 5: Summary of the intracellular metabolism and targets of MTX: 
 MTX is transported actively into the cell by RFC, where it undergoes polyglutamylation 
and exerts its toxic effects by inhibiting DHFR, TS and de novo biosynthesis of purines 
(PDNS). DHFR, dihydrofolate reductase;  DHF, dihydrofolate; THF, tetrahydrofolate; 
TS, thymidylate synthase; dTMP, deoxythymidine monophosphate; dUMP, deoxyuridine 
monophosphate; FPGS, folypolyglutamate synthetase; FPGH, folypolyglutamate 
hydrolase; MRPs, multidrug resistance-associated proteins; BCRP, breast cancer resistant 
protein; MTXGLs, MTX polyglutamates (Fotoohi 2008).           
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Pharmacogenetics of MTX and MTX-related toxicity and resistance: 
MTX dosing has traditionally been adjusted based on several prognostic factors such as 
age, weight, body surface or side effects. However, despite dose adjustments of MTX, 
some ALL patients do not respond well to MTX treatment [68]. Based on evidences, 
MTX causes severe dose-limiting adverse events, including ulcerative stomatitis, nausea, 
abdominal distress, fever and myelosuppression [28, 64]. Treatment-related toxicity is 
not only life threatening but also is one of the main reasons for early drug withdrawal, 
and subsequent increase in relapse risk [11, 55, 63]. In vitro or in vivo studies have shown 
that polymorphisms in genes encoding folate dependent enzymes may affect response to 
MTX [52]. Two important groups of genes are involved in MTX resistance. First group 
are genes that encode drug metabolizing enzymes and transporters which control 
pharmacokinetic properties and the second group includes genes that encode drug target 
and affects pharmacodynamic properties of MTX [52]. In regard to the latter, increase in 
DHFR and TS activity, due to overexpression of DHFR and TS gene is a common 
mechanism underlying resistance to MTX [28, 55, 73, 74]. Other important determinants 
of MTX resistance include decreased intracellular retention (caused by decreased 
polyglutamylation and decreased affinity of DHFR for MTX), qualitative and/or  
quantitative alterations in influx and/or efflux transporters, and expansion of the 
tetrahydrofolate (THF)- pool size in cells [55, 65, 74]. The cellular THF- pool is an 
important index of polyglutamation; cells with low level of THF pool are more sensitive 
to antifolates and large THF pool is associated with resistance to MTX and other 
antifolates, which require polyglutamylation for their activity within the cell [55, 70, 74]. 
DHFR is a member of the reductase enzyme family, is ubiquitously expressed in all 
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organisms. One of the major and critical roles of DHFR is maintaining intracellular THF-
cofactor pools at normal levels irrespective of the rate of synthesis of thymidylate  [74]. 
Reduction of DHFR enzymatic activity diminishes the THF pool inside the cell affecting 
the level of folate coenzymes and thus purine and pyrimidine synthesis [53, 75, 76]. 
MTHFR is another folate dependent enzyme, is not directly inhibited by MTX and 
inhibited by metabolites of MTX. This enzyme is influenced by MTX due to effects of 
MTX on the intracellular folate pool. MTHFR by converting 5-10 methylene-THF into 5- 
methyl-THF, provide a methylene group for homocysteine methylation resulting 
maintenance of homocysteine level in plasma [48, 49, 68, 77].  Moreover, MTHFR, as a 
major enzyme in folate and homocysteine cycles, has two famous known single 
nucleotide polymorphisms (SNPs), 677C>T and 1298A>C, associated with reduced 
enzyme activity. Both have been shown to alter sensitivity to MTX. In the case of 
677C>T polymorphism, it has been shown that the heterozygous 677CT have 65% of 
their enzyme activity whereas homozygotes 677TT have 30% of activity compared with 
the homozygous CC individuals (677CC). Likewise, homozygous CC1298 cells exhibit 
reduced enzyme activity [55].  Homozygosity for the 677T allele was associated with an 
increased risk of hepatotoxicity or myelosuppression adult ALL [78]. Based on 
association studies conducted in childhood ALL patients, there is no association of 677T 
allele with MTX-related toxicity. However based on recent studies, children with 
MTHFR polymorphisms developed more frequently myelosuppression and had higher 
creatinine levels [48, 79]. Beside folate dependent enzymes some other genes, like those 
involved in cell cycle regulation and apoptotic cascade, are also correlated with resistance 
to MTX [55] such as mutation in P53 gene [80] or apoptosis regulators Bcl-XL and Bcl-2 
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[81]. Cyclin D1 (CCND1) and retinoblastoma genes are key proteins involved in cell 
cycle regulation. They may as well play a role in MTX resistance, through increase in 
DHFR transcription. For example, CCND1 A870G polymorphism can modulate the ratio 
of CCND1 mRNA isoforms, favoring isoforms with longer half-life [82, 83]. The A870G 
polymorphism was associated with a significant increase in cancer risk including ALL 
and also affected response to treatment in ALL patients [84]. Overall, the molecular basis 
of resistance to antifolates, such as MTX, has been associated with target enzyme 
overexpression, change in the expression of a number of transporters and polymorphisms 
of genes affecting the activity of these proteins [65].  
 
Pharmacogenetic markers in MTX pathway of interest for this study: 
     
DHFR catalyzes the reduction of dihydrofolate (DHF) to THF which are needed for the 
action of folate dependent enzymes and thus are essential for DNA synthesis and 
methylation. DHFR inhibition by MTX diminishes the THF pool inside the cell affecting 
the level of folate coenzymes and thus purine and pyrimidine synthesis and finally 
causing cell death [36, 53, 68]. TS is a key enzyme in the nucleotide biosynthetic 
pathway that catalyzes conversion of deoxyuridine monophosphate (dUMP) to 
deoxythymidine monophosphate (dTMP) (Figure 5). TS is inhibited by MTXPGs, which 
leads to inhibition of purine and pyrimidine synthesis and inhibition of cell proliferation 
[36, 55, 65].                 
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1. DHFR gene polymorphisms: 
The functional gene is mapped at chromosome 5q11.2-13.2. Multiple intronless 
pseudogenes or dihydrofolate reductase-like genes have been identified on separate 
chromosomes [53]. The changes in DHFR expression or activity can be partly due to the 
functional polymorphisms in the DHFR gene, thereby influencing a risk of folate-
dependent diseases or affect response to antifolates. Association analysis performed in 
our group, identified particular DHFR haplotype that may affect the response to treatment 
in childhood ALL patients. The initial analysis of 15 DHFR minor promoter 
polymorphisms showed an association between homozygosity for A-317 and C-1610 
alleles  with lower event free survival (EFS) [85, 86]. Haplotype analysis identified an 
association with haplotype *1 harbouring both the A-317 and C-1610 alleles. Same 
haplotype was associated with higher DHFR expression, Further analysis performed in 
our lab, on the adjacent ~400-bp major DHFR promoter (located between minor and 
major transcript initiation sites) (Figure 6A) identified 6 polymorphisms, including 5 
single nucleotide polymorphisms (SNPs) and one length polymorphism composed of 
variable number of 9-bp elements and 9-bp insertion/deletion [85]. The haplotype 
analysis revealed diversification of haplotype *1 into five subtypes, (*1a to *1e) (Figure 
6B). Only *1b, conferred high transcriptional activity and was associated with lower EFS 
(Figure 6C). DFHR haplotype *1b is defined by particular allelic combination derived 
from three tag SNPs (C-1610G/T, C-680A and A-317G) in the minor promoter and three 
tag polymorphisms (C35T, G308A and compound length polymorphisms) in the major 
promoter [68, 85]. 
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Figure 6: DHFR risk haplotypes in major promoters: A. Structure of the human 
DHFR gene. The region of interest (~400-bp) is located between the minor and major 
transcript initiation sites indicated by arrows. B. Haplotype *1b includes six 
polymorphisms in the major promoter.  Tagging polymorphisms of the major promoter 
are at positions 35, 63/91, and 308. Haplotype *1b is composed  of three polymorphisms 
(C35T, G308A and compound length polymorphisms composed of 9-base pair (bp) 
insertion at position 63 and triple 9bp element at position 91) in the major promoter 
region. In major promoter lower event-free survival was associated with an A allele of 
G308A polymorphism and with haplotype *1b. C. The carriers of haplotype *1b showed 
reduced EFS (Dulucq 2008 and Al-Shakfa 2009). 
 
2. TS gene polymorphisms: 
Thymidylate synthase (TS) is an essential enzyme in folate metabolism, and is encoded 
by the TS gene located on chromosome 18p11.32. It plays a vital role in maintaining a 
balanced supply of deoxynucleotides required for DNA synthesis and repair by catalyzes 
conversion of dUMP to dTMP in the presence of 5, 10-methylenetetrahydrofolate 
(methylene-THF) [36, 65, 87].  TS is an important target for various chemotherapeutic 
and anticancer drugs, such as MTX and 5-fluorouracil. Inhibition of TS by methotrexate 
polyglutamates leads to inhibition of pyrimidine synthesis, deoxythymidine triphosphate 
depletion, cytotoxicity through thymineless death, uracil misincorporation into DNA, 
chromosome breaks and consequently to an inhibition of cell proliferation and cell death 
[74, 88]. TS also is a key enzyme in the nucleotide biosynthetic pathway that folate 
metabolism alteration due to functional polymorphisms in TS, were associated with 
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increased risk of hematological malignancies [55, 89]. Likewise polymorphisms in TS 
gene may affect response to cytotoxic drugs targeting this enzyme, such as MTX and 5-
FU [82, 88]. Three important polymorphisms have been well defined in TS gene; the 
variable number of 28-bp tandem repeats (VNTR) 2R or 3R polymorphism located on the 
5´-UTR enhancer region of the TS promoter (thymidylate synthase enhancer region 
[TSER]), the G>C substitution at the 12th nucleotide in the second repeat of the 3R allele 
(3RG>3RC) and the 6-bp deletion in the 3´untranslated region (3´UTR) (Figure 7) [36, 
73, 80, 90]. According molecular epidemiologic studies the majority of population 
harbour either a 2R or a 3R allele; however they have been shown four, five or nine 
repeats in African and Asian populations (Table 3).  It was shown that increasing number 
of repeats would increase the amount of several transcription factors mainly the upstream 
stimulating factors (USF) which stimulate transcription of TS [82]. Based on several 
studies, each of these polymorphisms can alter TS expression and consequently drug 
resistance and toxicity [87, 91]. The presence of a triple versus double 28-bp repeat in the 
enhancer region of 5'-UTR, has been associated with an increased TS expression both in 
vivo and in vitro studies [80-82]. Based on several studies, the 3R/3R genotype has been 
identified as a predictor of poor clinical outcome to MTX-based chemotherapy in 
childhood ALL patients (Figure 8) [73, 92]. It might be hypothesized that inhibition of 
3R/3R genotype, requires higher concentrations of MTX in comparison to other 
genotyping groups to efficient target inhibition [68]. In addition to tandem repeat 
sequence G to C polymorphism in the second repeat element of the 3R allele (3RC vs. 
3RG) of TS gene, can influence gene expression and TS mRNA transcriptional and 
translational efficiency [73, 87, 93]. This SNP can further diversify the 3R allele into 
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either 3C or 3G, the 3G alleles seems to affect mRNA expression and catalytic activity of 
TS and also was associated with poor response to MTX in some studies  [73, 80, 83]. Our 
group has studied the effect of substitution in 3RG allele on ALL outcome [73].  
Although the 3RG3RG individuals had lowest EFS, we did not notice significant 
difference between 3R3R subgroups (Figure 9) [73]. A double repeats (2R) of 28-bp 
polymorphism in the TS promoter enhancer region is associated with lower expression of 
the gene and the individuals with this allele may be more prone to toxic effects as shown 
in several studies [94]. The 6-bp deletion in the 3´UTR of TS gene can play a role in 
mRNA stability and translation [90, 95, 96]. 6-bp deletion allele being associated with 
decreased TS mRNA stability and expression [80, 87, 95]. This polymorphism was show 
to affect sensitivity to anticancer drugs and prognoses of breast and gastrointestinal 
cancers [96, 97]. Krajinovic et al (2005), combined TS polymorphisms for the analysis, 
and found lower frequency of the 2R6 bp- haplotype among children with an event, 
whereas 3R homozygosity combined with 6 bp+ alleles, seems to potentiate lower EFS 
(Figure 10) [73].   
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Figure 7: TS gene important polymorphisms: 
The variable number of 28-bp tandem repeats (2R or 3R) in the 5´untranslated region 
(5´UTR); the G>C substitution at the 12th nucleotide in the second repeat of the 3R allele 
(3RG>3RC) and the 6-bp deletion in the 3´UTR (+6bp/-6bp 3´UTR) region (Modified 
from Lima 2013). 
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Table 3: TS polymorphisms characteristics: 
2/3/4/5/9 represents the possible number of repeats. Del: Deletion; ins: insertion; VNTR: 
Variable number tandem repeat (Lima 2013). 
 
rs ID Polymorphism Alleles Type Region Putative 
biochemical 
effects 
 
rs34743033 TSVNTR 28 bp (CCGCGCCACTTCGCCT
GCCTCCGTCCCG) 
2/3/4/5/9 
VNTR 5´-UTR mRNA 
translational 
efficiency and 
TS expression 
 
rs2853542 TS SNP C>G C/G SNP 5´-UTR mRNA 
translational 
efficiency and 
TS expression 
 
rs34489327 TS 1494del6 –/TTAAAG Del/ins 3´-UTR mRNA stability 
and TS 
expression 
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Figure 8: Event-free survival (EFS), for patients with and without TS 3R/3R 
genotype: ALL patients with 3R3R genotype had lower event-free survival (Krajinovic 
2002). 
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Figure 9: Effect of 28-bp repeat variation genotypes following stratification of 3R 
allele on 3RC and 3RG: Impact of EFS for ALL patients: EFS curves are given for 2R 
carriers (2R*) and each 3R/3R subgroup (3RG/3RG, 3RC/3RG, 3RC/3RC).  3RG/3RG 
individuals have lower EFS however the difference was not significant when compared to 
other 3R3R subgroups (Krajinovic 2005).    
 
  
                            
Figure 10: EFS for ALL patients following stratification of 3R3R genotypes by 6 
bp+/- polymorphism: The lower curve represents EFS for patients who are both 
homozygous for 3R variant and the carriers of 6 bp+ allele. The upper curve represents 
EFS for individuals without these TS genotypes. The genotype and the number of 
patients in each curve and numbers of individuals with an event are in the parenthesis 
(Krajinovic 2005). 
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Combined effect of DHFR and TS genes; impact of MTX metabolic 
pathway: Based on previous study in our lab, promoter haplotype *1b of DHFR and 
homozygosity for 3R repeat of TS gene are relapse-predisposing (at risk) genotypes. Given 
that both DHFR and TS belong to the sub-pathway of MTX action, the relapse rate is further 
increased if these two at risk genotypes are combined (Figure 11) [73, 85, 86]. 
 
 
A) 
 
                                                              DHFR 
 
B)  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
EFS 
*1b-3R3R+ 
*1b+3R3R- 
*1b+3R3R+ 
P<0.0005 
*1b+3R3R- 
*1b-3R3R+ 
P<0.0005 
*1b+3R3R+ 
 
 
THF 
dUMP dTMP 
TS 
MTX 
DHF 
MTX (Glu)n 3R3R 
*1b 
*1b-3R3R- *1b-3R3R- 
All patients High-risk patients 
EFS 
 36 
 
Figure 11: Combined effect of DHFR haplotype *1b and TS 3R/3R genotypes on 
EFS in patients with ALL.  
Haplotype *1b of DHFR and homozygosity for 3R repeat of TS gene are risk genotypes. 
Both risk genotypes are associated with higher expression of respective genes, possibly 
resulting in resistance to MTX, thus explaining reduction in EFS in patients with these 
genotypes. The EFS is further decreased if these two at risk genotypes are combined.  All 
patients regardless of risk groups are presented in A and only high risk patients are 
presented in B. (Al-Shakfa 2009 and unpublished results).                                                 
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                                       Part III                      
L-Asparagines (ASNase) - standard component in the childhood ALL 
treatment: 
ASNase is an essential and standard component of multi-agent chemotherapy in the 
childhood lymphoblastic leukemia treatment. ASNase is used in both induction and post-
induction phases of ALL treatment protocols [3, 26, 98].  The logic behind the ASNase 
therapy is rapid efflux of cellular asparagine, needed for protein biosynthesis and cell 
survival. Most cells express sufficient asparagine synthetase (ASNS) except leukemic 
cells which are thus dependent on circulating asparagine levels that are in turn depleted 
by ASNase treatment. The mechanism underlying the activity of asparaginase relies on 
the conversion of asparagine into aspartate and glutamate [98-100]. Different kind of 
ASNase preparations are used in childhood ALL treatment protocols, including; 
Escherichia coli (E. coli), polyethylene glycol–conjugated (PEG) and Erwinia ASNase. 
E. coli ASNase and PEG- ASNase are derived from E. coli whereas Erwinia ASNase is 
derived from the Erwinia chrysanthemi bacteria [92, 99, 101]. E.coli derived 
asparaginase seems to have higher efficacy. Fewer doses requirement per treatment 
period and longer half-life as well as its lower immunogenicity are the advantages of 
using PEG- ASNase [99]. In vitro experiments conducted in leukemia cell lines and 
patient lymphoblasts, showed that asparaginase resistance in ALL can be related to an 
increase of ASNS activity [36, 102]. A significant improvement in overall survival (OS) 
and event free survival (EFS) was seen for children with ALL who received ASNase 
during post remission consolidation compared with those who did not receive ASNase. 
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Associations between treatment outcome and ASNase dose intensity and between an 
inferior outcome and the use of ASNase preparation with a shorter half-life have been 
reported. ASNase intolerance produces allergic reactions, pancreatitis, and abnormalities 
of haemostasis. These ASNase associated complications may also affect treatment 
outcome [102, 103]. 
 
ASNase-related toxicity and resistance: 
 
Several genes are involved in antileukemic effect of asparaginase. Polymorphisms in the 
asparaginase synthetase gene (ASNS) and the basic region leucine zipper activating 
transcription factor 5 (ATF5), have been associated to lower event-free survival of ALL 
patients [102]. Differences in susceptibility to ASNase have long been attributed to 
variable levels of asparagine synthetase (ASNS) expression. In vitro experiments 
conducted in leukemia cell lines suggested that elevated ASNS levels might be a cause of 
ASNase resistance and that ASNS inhibitors may suppress a proliferation of resistant cell 
lines. It has been shown that leukemic cells can up-regulate ASNS gene expression under 
nutrient stress caused by ASNase [102]. Recently suggested mechanism of asparaginase 
resistance includes protection of leukemic lymphoblasts against asparaginase cytotoxicity 
by bone marrow mesenchymal cells (MSC) niches due to high asparagine levels and 
excess asparagine production, provided by higher activity of ASNS in these cells (Figure 
12) [98, 104] In vitro studies have shown that ASNS plays a role in mediating drug 
resistance, especially in T-ALL cells and B cells with ETV6-AML1 or hyperdiploidy 
anomalies. Based on evidences there is an inverse correlation between the ASNS protein 
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and ASNase-induced cell death. Using genome-wide expression profiling and patient 
samples, revealed that ASNase-resistant, TEL-AML1–negative B cells had significantly 
higher ASNS mRNA expression compared with sensitive ones [105].  An increase in 
ASNS expression was predictive of inferior disease outcome. Whereas other groups 
reported an absence of association between ASNS expression and in vitro response to 
ASNase when patient lymphoblasts were analyzed [102]. Acute adverse effects of 
ASNase  therapy such as allergic reaction and hypersensitivity [101, 106],  pancreatitis 
[106], cerebrovascular accidents [107],  hyperglycaemia secondary to hypoinsulinaemia, 
hypolipoproteinaemia and hypoalbuminaemia are a significant source of morbidity and 
may increase relapse risk in patients unable to receive all intended doses [101, 106]. The 
anti-leukaemia effect of ASNase is related to asparagine depletion. Prolonged asparagine 
depletion is also associated with the development of coagulation defects. Thus 
asparaginase-related thrombosis is a significant complication of ALL therapy in children 
and adults [106, 107]. Arginosuccinate synthase 1 (ASS1) is involved in catalyzing the 
conversion of aspartate and citrullin into argininosuccinate, which may affect level of 
aspartate needed for asparagine synthesis. In vitro experiments and microarray analysis 
identified association between up-regulation of ASS1 in cell lines and resistance to 
ASNase and in turn, ASS1 mRNA suppression restores ASNase sensitivity in resistant 
cell lines [102, 108]. 
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Figure 12: Protection of leukemic lymphoblasts with bone marrow MSCs; Impact of 
ASNS role in resistance to ASNase: Asparagine, produced in large amounts by bone 
marrow mesenchymal cells, protects leukemic blasts from the asparagine-depleting 
effects of ASNase treatment (Williams 2007).   
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Pharmacogenetic markers in ASNase pathway of interest for this study: 
ASNS, ATF5 and ASS1 have been shown to mediate the antileukemic effect of ASNase 
by providing variable expression between leukemia cells that are resistant and sensitive to 
treatment [102, 103]. Microarray analysis identified up-regulation of ASS1 in cell lines 
with resistance to asparaginase. Recent genome-wide analysis identified an association of 
ASS1 polymorphisms with in vitro asparaginase sensitivity in ALL patient samples and 
HapMap cell lines. Although, GWAS showed implication of ASS1 in in vitro sensitivity, 
but there is no data showing association of ASS1 with EFS [102]. Rousseau et al, 
recently analyzed the genes in asparaginase pathway and found that C1562T allele in the 
5’UTR of the gene coding for transcription factor ATF5, which regulates ASNS levels, is 
associated with higher promoter activity and confers higher risk of ALL relapse in 
patients who received E.coli ASNase (Figure 13A) [102]. ATF5 involved in several cell 
regulatory process such as cellular differentiation, cell cycle, and apoptosis [102].  ATF5 
as a stress response transcription factor and responds to amino acid limitation. In the case 
of nutrition deprivation, ATF5 can bind to the nutrient-sensing response unit of the ASNS 
gene and acts as a transcriptional activator of ASNS [102, 109]. Several haplotypes have 
been distinguished in ATF5 gene located in the regulatory region (including the 5' UTR 
and the 2-kb element upstream from the transcription start site), which can affect 
promoter activity and mRNA levels. Also several haplotypes were shown by luciferase 
assay to affect promoter activity [102].  Based on Rousseau et al, among these 
haplotypes, only haplotype tagged by T1562 alleles was associated with reduced EFS in 
ALL in two independent patient cohorts (Figure 13B). This association was limited to 
ALL patients that received E coli asparaginase, which might be related to higher activity, 
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of this drug formulation [102]. According in vitro experiments conducted in leukemia 
cell lines and patient lymphoblasts, one of the main factors of ASNase resistance is 
elevated ASNS activity. Based on Rousseau et al. data, promoter variant of 
transcriptional factor ATF5 involved in ASNS regulation is associated with higher 
promoter activity and confers higher risk of ALL relapse in patients who received E.coli 
ASNase. ASNS gene has tandem repeated sequences as a polymorphism of the ASNS gene 
and it can function as a transcriptional enhancer element; as insertional sequences or 
increased number of tandem repeat might be involved in gene expression and increased 
activity [102, 105]. Two 14-bp tandem repeat (2R) sequences in the promoter region of 
the ASNS gene is located in the first intron of the gene. Approximately 75% of ALL 
patients carry 2R sequence in both allele, whereas 20% and 3% ALL patients had 3R and 
4R, tandem repeats in one allele, respectively [105]. Our association analysis between 
polymorphism in ASNase pathway and ASNase-related acute complications (allergies, 
pancreatitis and thrombotic events), showed an association of 3R3R genotype of ASNS 
gene, with a higher frequency of ASNase–related adverse reactions. The protective role 
of haplotype harbouring 2R allele against ASNase toxicities has been also found (Figure 
14) [103].   
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B 
                                   
Figure 13: ATF5 gene polymorphisms and EFS for patients with ALL according to 
ATF5 genotypes:  A; Tag SNPs (sufficient to define common haplotypes) with 
frequency ≥5% in patients comprising 8 SNPs includes C1562T polymorphism (red 
arrow) in ATF5 promoter. B; EFS curves are shown for patients who were carriers (T+; 
dark gray) or not (T-; light gray) of the T1562 allele. EFS curves are presented for all HSJ 
and DFCI patients who were assigned to E coli asparaginase. The number of all patients 
in each curve (with the number of cases with an event in brackets) is indicated next to the 
curve. (Rousseau 2011).        
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Figure 14: Tandem repeat polymorphism of ASNS gene in relation to allergies and 
pancreatitis in ALL patients of discovery cohort: 
The frequency of individuals with genotypes of tandem repeat polymorphism in patients 
with (+, dark gray bars) and without (–, light gray bars) allergies and pancreatitis (left and 
right side panel, respectively) (Ben Tanfous 2014). 
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Hypothesis and Objectives:   
ALL is the most frequent malignancy of childhood. The relapse and drug-related adverse 
events may hamper the success of treatment and may be modulated among other factors 
by patient genetic background. ALL treatment protocols include several 
chemotherapeutics imposing the question whether an association observed in clinical 
setting results from an association between a given polymorphism and a single drug or it 
results from interaction with other chemotherapeutics. Understanding the mechanism 
governing associations found in clinical setting is essential to define how to best tailor the 
treatment according to patient genotype. The work presented in this thesis builds on the 
finding of our research group interrogating relationship between gene variants of MTX 
and ASNase pathway and therapeutic responses in ALL patients [1-5]. 
These finding include: 
i) Association between genetic variations of MTX action pathway and ALL outcome 
indicated a higher risk of relapse in patients who are homozygous for triple repeat (3R) 
allele of TS gene and/or have  *1b  haplotype defined by particular allelic combination of 
polymorphisms in the promoter of DHFR gene. Both variations are associated with an 
increase in respective gene expression, suggesting that lower sensitivity to MTX 
associated with these variations might be a cause of higher risk of relapse and reduced 
disease free survival in patient with ALL [1-3]. Higher DHFR expression associated with 
haplotype *1b results in higher tetrahydrofolate levels, whereas higher TS expression 
associated with 3R allele might produce enough nucleotides required for DNA synthesis 
preventing initiation of a DNA damage response pathway and apoptosis [6, 7]. This 
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would suggest that patients with particular DHFR or TS genotypes might need higher 
doses of MTX to effectively inhibit DHFR and/or TS targets. 
ii) Promoter variant of transcriptional factor ATF5 involved in ASNS regulation, is 
associated with higher promoter activity and confers higher risk of ALL relapse in 
patients who received E.coli ASNase [4] Polymorphisms of ASNS gene located in 
enhancer repeat element affected risk of relapse and frequency of ANSase-related 
complication. Differences in sensitivity to ASNase have been attributed to variable levels 
of ASNS expression which may counteract the ASNase effect and underlie the resistance 
to treatment, or, may mediate higher sensitivity to treatment and possibly higher 
frequency of ASNase-related complications [5]. 
 
Hypothesis: The observed associations between genetic variations and increased risk of 
ALL relapse and or drug-related toxicity observed  in clinical setting result from genetic 
driven change in sensitivity to particular components of multi-agent treatment protocol.  
Major goal of my PhD project was to assess the functional role of genetic variations of 
MTX and ASNase action pathway that were found in clinical setting to affect the 
treatment response in childhood ALL, using lymphoblastoid cell lines and xenograft 
mouse model of ALL. 
              The specific aims of this study were:  
i) To analyze the effect of TS polymorphism on MTX sensitivity using cellular 
proliferation assay and xenograft mouse mice model of ALL. 
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ii) To analyze the effect of DHFR polymorphism on MTX sensitivity using cellular 
proliferation assay. 
iii) To analyze the effect of ATF5 and ASNS genes polymorphisms on sensitivity to E.coli 
ASNase using in vitro proliferation assay.      
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Materials & Methods: 
A. In vitro proliferation assay in response to MTX and ASNase 
                                            
A.1. Cell viability test: 
 
Lymphoblastoid cell lines (LCLs) originating from CEPH (Centre d’Étude du 
Polymorphisme Humain) families were used. CEU cell lines (each originating from 
different individual of Northern and Western European ancestry), were purchased from 
Coriell Cell Repositories. In vitro sensitivity to MTX and ASNase were assessed in 93 
and 89 LCLs respectively. LCLs (5 x104 cells) were incubated with different drug 
concentrations of MTX ranging from 0.001- 100 μM and E.coli ASNase from 0.01-10 IU 
in 96-well plate, followed by addition of a cell proliferation reagent WST-1 [sodium 5-(2, 
4-disulfophenyl)-2-(4-iodophenyl)-3-(4-nitrophenyl)-2H tetrazolium inner salt], which is 
reduced to coloured formazan by living cells only. The amount of formazan dye formed 
directly correlates to the number of metabolically active cells in the culture. The 
formazan production is quantified using a spectrophotometer at 450 nm. The optical 
density (OD) is linearly related to the cell number. The drug concentration resulting in 
50% inhibition of cell growth (IC50) during 96h for MTX and 48h for ASNase incubation 
times was estimated (Figure 1). Cellular viability was calculated at each drug 
concentration by the equation: (OD treated well/OD control wells) x 100%. IC50 values 
were estimated using the GraphPad software by fitting sigmoid dose-response curves. 
Relationship between genetic variants of interest in DFHR, TS, ATF5 and ASNS genes, 
and IC50 values were assessed by ANOVA or nonparametric tests depending on data 
distributions and homogeneity. The cell lines were also grouped based on IC50 values in 
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groups with sensitive, resistant and intermediate phenotype and the correlation was 
performed by chi-square. 
 
 
 
 
 
Figure 1: Lymphoblastoid cell lines treated with MTX and ASNase: 
Lymphoblastoid cell lines were treated with different concentration of (A) MTX (0.001- 
100 μM) and (B) ASNase (0.01-10 IU). Left side graphs indicate an example of sensitive 
and right side of resistant cell lines. Cell viability test with cell proliferative reagent, 
WST-1 (10 μl/ well). IC50 values are indicated. 
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A.2. Genotyping: 
 
 DNA is extracted from these cells and genotyping performed to define presence or 
absence of genetic variant of interest (*1b of DHFR, 3R3R of TS, ATF5 T1562C 
substitution and ASNS polymorphism). DFHR haplotype *1b is defined by particular 
allelic combination derived from three polymorphic site (C-1610G/T, C-680A and A-
317G) in the minor promoter and three polymorphisms (C35T, G308A and length 
polymorphisms at positions 63/91) in the major promoter.  Genotyping of nucleotide 
substitutions is performed by polymerase chain reaction (PCR) followed by allele-
specific oligonucleotide (ASO) hybridization.  Presence or absence of TS triple repeat, 
3R/3R genetic polymorphism and of ASNS tandem repeat were resolved by polymerase 
chain reaction (PCR) amplification followed by 3% agarose gel electrophoresis at 85V 
for 1h30 for TS (Figure 2), and 4% agarose gel electrophoresis at 70V for 2h30 for ASNS 
genetic polymorphisms. The genotypes of remaining ASNS polymorphisms for each CEU 
LCLs were obtained from HapMap site (http://hapmap.ncbi.nlm.nih.gov/). 
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2R/2R                            3R/3R           2R/3R 
 
 
 
Figure 2: TS triple repeat (3R) 28 bp genotyping:  
Lymphoblastoid cell lines performed for TS triple repeat (3R) 28 bp genotyping. 
The presence or absence of TS triple repeat, 3R/3R genetic polymorphism was resolved 
by polymerase chain reaction (PCR) amplification. PCR amplification was followed on 
3% agarose gel electrophoresis at 85V for 1h30. 
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B. in vivo xenograft mouse model of human ALL: 
B.1. Patient samples:  
Bone marrow aspirates were obtained from newly diagnosed paediatric ALL patients 
treated at the CHU Sainte-Justine (Montréal, Canada). The patient’s samples were 
collected on heparinized tubes and bone marrow mononuclear cells (BMMC) were 
obtained after Ficoll-Hypaque (GE Healthcare) density gradient centrifugation. BMMC 
were cryopreserved in DMSO 10% for later use. The study has been approved by the 
Institutional Ethical Review Board in Research of the CHU Sainte-Justine and an 
informed consent was obtained from the patients and/or their parents.  
 
B.2. Xenograft mouse model of human ALL:  
 
NSG mice (NOD/LtSz-scid IL-2Rγc null, Jackson Laboratory) were bred and maintained 
under specific pathogen-free conditions in micro-isolator cages and provided with 
autoclaved food and water in the research animal facility of the CHU Sainte-Justine.  
BMMC samples were thawed and evaluated for phenotypic analysis of blasts content by 
flow cytometry. Patient’s blasts were expanded in a primary round of in vivo expansion 
by injecting between 5 x106 thawed ALL patient blasts in the lateral tail vein of one to 
three non-irradiated NSG mice. In order to deplete the T lymphocytes present in the 
sample that may have caused a xeno-Graft-versus-Host Disease (GvHD) in the primary 
injection, mice received anti-CD3 antibody. Mice were evaluated for leukemia 
development by detection of circulating human blasts in the blood by flow cytometry. 
The mice were sacrificed when human blasts were ranging from 30-90% of total CD45 
 61 
 
and/or CD19 and/or CD10-positive lymphocytes. The spleen was then crushed on a 
70μm strainer using PBS. Human blasts were phenotyped and enumerated by flow 
cytometry.  
 
B.3. MTX treatment: 
For the assessment of MTX sensitivity, after optimisation experiments (Figure 3), 7- to 
10-week-old NSG mice were injected intravenously with 5x106 in vivo expanded pre-B 
patient’s leukemic blasts with and without TS 3R/3R genotype. When the percentage of 
human ALL blasts reached 1-5% of CD45+ and/or CD19+ and/or CD10+ cells in 
peripheral blood, mice were randomized to receive MTX (Accord Healthcare) intra-
peritonealy in groups of 5 individuals at either 0.25; 1 or 5 mg/kg/day or PBS (negative 
control) on 4 consecutive days, every 14 days for a maximum of 8 weeks when possible. 
Peripheral blood was weekly collected from the saphenous vein on Microvette-200 
heparinized tubes (Sarstedt). Red blood cells were lysed using ammonium chloride 0.3 M 
solution and cells were then analyzed by flow cytometry analysis. B-cell-specific markers 
(as determined by flow cytometry) and genotyping of TS locus was used to evaluate blast 
phenotype and consistency of genotype after transplant. Mice were sacrificed at the end 
of MTX treatment or when they reached established limit points (hunch-back, weight loss 
and ruffled fur, performed in blinded fashion as to assigned treatment). Limit points were 
assessed every day and determined by our internal committee for good animal practices 
in research.  
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B.4. Flow cytometry analysis:  
Flow cytometry analyses of xenograft leukemia cells in peripheral blood and spleen were 
performed using monoclonal antibodies specific for murine CD45 conjugated with 
fluorescein isothiocyanate (FITC), anti-human CD45 conjugated with allophycocyanin 
(APC), anti-human CD19 conjugated with phycoerythrin (PE), anti-human CD3 
conjugated with BD Horizon V500, and anti-human CD10 conjugated with 
phycoerythrin-cyanine7 (PE-Cy7) (from BioLegend). Dead cells were excluded by 7-
amino actinomycin D (7-AAD) staining (BD Biosciences). Count Bright Beads (Life 
Technologies) were added in each tube for absolute counts determination. Flow 
cytometry analysis was performed using an LSRFortessa flow cytometer (BD 
Biosciences). The development of leukemia in mice was determined by estimating the 
proportion of human cells among total lymphocytes (human + murine) and by estimating 
the absolute counts of blast cells. The results were analyzed using FCS Express 4 for 
Flow Cytometry RUO Edition (De Novo Software).   
B.5. Statistical analysis:  
Results were analyzed using GraphPad Prism 4.0 (GraphPad Softwares Inc., La Jolla, 
USA) and are shown as mean ±SEM. Elsewhere, two-tailed Mann-Whitney tests were 
used with significance set at P ≤ .05.   
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Figure 3: MTX efficacy assessment in NSG mice, optimization experiments:  NSG 
mice showed expansion of leukemia cells about four weeks after receiving leukemia 
cells. MTX treated group showed significant reduction of leukemia cells in comparison 
with PBS control group, just one week after treatment with MTX. One week after drug 
withdrawal, MTX treated group showed increase of leukemic cells. 
 
 
The results assessing in vivo approach using xenograft mouse model are presented in the 
article 2.
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Abstract:  
Dihydrofolate reductase (DHFR) catalyzes the reduction of dihydrofolate to 
tetrahydrofolate (THF). THF is needed for the action of folate-dependent enzymes and is 
thus essential for DNA synthesis and methylation. The importance of this reaction is 
demonstrated by the effectiveness of antifolate medications used to treat cancer by 
inhibiting DHFR, thereby depleting THF and slowing DNA synthesis and cell 
proliferation. Due to the pivotal role that DHFR plays in folate metabolism and cancer 
treatment, changes in the level of DHFR expression can affect susceptibility to a variety 
of diseases dependent on folate status such as spina bifida and cancer. Likewise, 
variability in DHFR expression can affect sensitivity to anti-cancer drugs such as the 
folate antagonist methotrexate. Alterations in DHFR expression can be due to 
polymorphisms in the DHFR gene. Several variations have recently been described in 
DHFR, including promoter polymorphisms, the 19-bp deletion allele and variations in 
3’UTR. These polymorphisms seem to be functional, affecting mRNA levels through 
various interesting mechanisms, including regulation through RNA interference. Several 
groups have assessed the association of these polymorphisms with folate levels, risk of 
cancer and spina bifida as well as the outcome of diseases treated with MTX. The latter 
may lead to different treatment schedules, improving treatment efficacy and/or allowing 
for a reduction in drug side effects. This review will summarize present knowledge 
regarding the predictive potential of DHFR polymorphisms in disease and treatment. 
Keywords: Gene, dihydrofolate reductase (DHFR), polymorphisms, disease 
susceptibility, methotrexate (MTX), therapeutic response 
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INTRODUCTION 
Dihydrofolate reductase (DHFR) is a member of the reductase enzyme family, which is 
ubiquitously expressed in all organisms. At the transcriptional level, DHFR is governed 
by a TATA-less promoter that is controlled by numerous transcription factors, including 
Sp1 and E2F that are important for its regulation throughout the cell cycle [1, 2]. Levels 
of this enzyme peak at the G1/S cell cycle boundary. Autoregulation, through DHFR-
RNA interactions, has also been reported [3, 4]. DHFR catalyzes the NADPH dependent 
reduction of dihydrofolate (DHF) to tetrahydrofolate (THF) needed for several one-
carbon transfer reactions in purine and pyrimidine synthesis [2]. DHFR is also needed 
for the intracellular conversion of synthetic folic acid, consumed in supplements and 
fortified foods, into the THF forms that can participate in folate/homocysteine 
metabolism. Reduction of DHFR enzymatic activity diminishes the THF pool inside the 
cell affecting the level of folate coenzymes and thus purine and pyrimidine synthesis [1]. 
This may as well influence homocysteine levels and methylation processes, since methyl-
THF is needed for the remethylation of homocysteine to methionine, thereby ensuring the 
provision of S-adenosylmethionine (SAM) necessary for most biological methylation 
reactions [5]. DHFR inhibition is essential to the action of antifolate medications used to 
treat cancer and some inflammatory diseases [6-9]. The DHFR gene family includes the 
functional DHFR gene and four other intronless pseudogenes (DHFRP1–4) [10]. The 
functional gene is located at chromosome 5q11.2- 13.2 and is expressed in three mRNA 
isoforms with alternatively spliced 3’UTR ends [11]. The changes in DHFR expression 
or activity can be partly due to the functional polymorphisms in the DHFR gene, thereby 
influencing a risk of folate-dependent diseases. Importantly, gene variations may also 
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affect therapeutic responses to antifolates, leading to lower treatment efficacy or higher 
adverse drug event frequency. This review will summarize several studies that analyzed 
whether DHFR gene polymorphisms may affect disease susceptibility or antifolate 
treatment outcomes. 
 
DHFR POLYMORPHISMS AND DISEASE SUSCEPTIBILITY 
 
Neural tube defects (NTD) are a group of common birth defects with a prevalence of 
approximately 1 per 1,000 in Europe [12]. It is well documented that low serum folate 
and high homocysteine levels are associated with an increased risk of NTD, explaining 
the preventive effect of folic acid supplement [13, 14]. Change in activity of the folate 
cycle enzymes may affect the folate levels and affect NTD development. It is, therefore, 
not surprising that polymorphisms of folate-dependent enzymes of both mother and child, 
such as methylene tetrahydrofolate reductase (MTHFR), have been shown to contribute to 
the risk of NTD [15, 16]. Neural tube closure occurs during a period of rapid cellular 
proliferation and DHFR activity may be a crucial factor in maintaining optimal DNA 
synthesis during this time [13]. The most extensively studied DHFR polymorphism is a 
19bp insertion to deletion in the first intron that has been evaluated as a risk factor for 
NTD in several studies (Table 1). Johnson et al. 2004 [17], suggested that the deletion 
(del) allele could affect gene expression, since the Sp1 transcription factor binding site is 
located within the deleted sequence. The first, a small case-control study, provided 
evidence that the risk of having a child with spina bifida is higher for women with the 
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DHFR 19bp del/del genotype than it is for those with the remaining genotypes [17]. The 
same authors [18] reported a higher risk of pre-term delivery in patients with the del 
allele. Van der Linden et al., 2007 [19], reported an absence of association between 
del/del genotype and spina bifida risk, whereas Parle-McDermott et al., 2007 [13], 
observed a lower risk of having a child with NTD in women with the del allele. It has 
also been reported that individuals with the del/del genotype have lower homocysteine 
[20] and increased serum and red blood cell folate levels [14]. A nonsignificant 
increase in mRNA levels for homozygous del individuals [13], and subsequently a 
significant increase in DHFR expression with the number of del allele [21], were 
reported. This would support the possible maternal protective role of the 19-bp del allele 
in NTD by increasing the amount of DHFR available to reduce DHF to THF. However, 
others reported an absence of association between del allele and mRNA levels [19] or 
even suggested in the recent cross-sectional, population-based study [22] that the del/del 
genotype resulted in a diminished capacity of the enzyme to reduce folic acid. It seems 
that the role of DHFR polymorphisms in NTD risk still remains to be determined, since 
results regarding 19bp del allele are inconclusive. The abrogation of the Sp1 binding site 
by the deletion allele or its close location to the splice donor site (60bp) may suggest a 
functional role of this polymorphism, yet contradictory results have been obtained. 
The other polymorphisms that are in linkage disequilibrium (LD) with 19bp insertion to 
deletion variation may be responsible for the observed results or discrepancies. Indeed, 
the high extent of LD was noted in the DHFR gene with 19bp insertion to deletion being 
in LD with the promoter polymorphisms [23]. The same polymorphism is shared among 
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several haplotypes, showing the necessity of estimating the impact based on the analysis 
of both individual polymorphisms and haplotypes. In some instances the haplotypes 
may provide more precise information for predicting disease risk than individual 
polymorphisms [24]. DHFR is an important folate cycle enzyme required for nucleic acid 
synthesis as well as homocysteine remethylation, suggesting that DHFR polymorphisms 
may play a role in cancer susceptibility as well. It is possible that similarly to MTHFR, 
the DHFR gene variations may play a dual role. Polymorphisms associated with a higher 
expression of DHFR may protect against cancer, due to the higher levels of 5,10-
methylene-THF needed for thymydylate synthesis, whereas a change in the 5-methyl-
THF pool may affect methylation reactions and, consequently, increase cancer risk. Both 
genomic DNA hypomethylation and gene-specific promoter CpG island 
hypermethylation are important epigenetic mechanisms of carcinogenesis [5, 25]. Indeed, 
a protective role of the DHFR 19 bp del allele in adult acute lymphoblastic leukemia 
(ALL) patients has been reported [26], which was further potentiated when the del allele 
was combined with the TT677 genotype of MTHFR, previously shown in several studies 
to reduce the risk of ALL [27, 28]. Analysis of the DHFR 19-bp insertion to deletion 
polymorphism in relation to breast cancer susceptibility did not reveal a significant 
association with overall breast cancer risk [21, 29]. However, when analyses were 
performed following stratification according to multivitamin use [21], an association 
appeared significant in patients that used the multivitamin supplements. Individuals with 
the del/del genotype had a 50% increase in breast cancer risk compared with individuals 
without this genotype [21]. Although several cohort studies suggested that higher folate 
intake was associated with lower breast cancer risk, a recent large screening trial showed 
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that higher supplement intake may increase the risk of breast cancer in postmenopausal 
women [30]. The authors [30] further hypothesize that, because of the complexity 
of folate function, it is possible that both deficiency and abundance of folate may 
contribute to breast carcinogenesis at different stages of tumor development or in 
different tumor phenotypes. It is thus possible that genetic variations along with dietary 
intake of folate and methionine influence cellular one carbon metabolism and methyl-
donor status, which may also affect susceptibility to other cancers such as colorectal 
carcinoma. Recent studies have shown the potential relationship between germline 
variants in methyl-group metabolism genes and promoter CpG island methylation in 
colorectal tumors [31], which seems to be a specific molecular pathway for colon 
carcinogenesis. Curtin et al. [32] looked into an association among genetic 
polymorphisms relevant to folate mediated one-carbon metabolism, including DHFR 19-
bp insertion to deletion polymorphism and colon cancer risk, but did not find any 
association with the del allele [32]. In contrast, a large population-based study that 
analyzed 395 tag SNPs (a sufficient number of polymorphisms to define common 
haplotypes, as based on LD) in 15 folate-pathway genes identified two tag SNPs in the 
DHFR gene (intronic rs1677693 A to C and rs1643659 A to G polymorphisms) 
associated with lower colorectal cancer risk [33]. The analyzed population was on a 
folate fortified diet, but the observed protective effect was particularly obvious in non– 
multivitamin supplement users, confirming previous observations that the effect of folate 
cycle gene variants may be potentiated or abrogated by dietary folate intake. 
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DHFR GENE POLYMORPHISMS AND RESPONSE TO TREATMENT 
 
The same gene variations that favour THF accumulation may both protect against cancer 
establishment (as shown in ALL patients [26]) and affect antifolate treatment being 
responsible for individual differences in terms of survival. This paradoxical dual and 
opposite effect was recently described as ‘‘false-friend allele’’ behavior [26], and has 
also been previously noted for MTHFR variant alleles [34]. Higher DHFR activity and 
THF accumulation can contradict a cyto- toxic effect of antifolates, thereby reducing 
treatment efficacy. Methotrexate (MTX) is an important antifolate widely used in the 
treatment of several malignancies, including acute lymphocytic leukemia, non-Hodgkin's 
lymphoma, osteosarcoma and choriocarcinoma [35]. DHFR, as a major MTX target, 
plays an important role in the development of MTX resistance in ALL. In both 
experimental and clinical settings, altered levels of DHFR and/DHFR gene amplification 
were found in relapsed leukemia patients and in leukemia and colon cell lines 
manifesting MTX-resistant phenotypes [8, 36-38]. Of note is that several mechanisms 
may contribute to the development of MTX resistance. This review is, nevertheless, 
limited only to DHFR gene variations and other mechanisms are reviewed in detail 
elsewhere [9]. Regarding the potential role of DHFR polymorphisms in response to MTX 
treatment (Table 1), Goto et al., 2001 [39], described one of the first variations in DFHR 
while analyzing the 3'-untranslated region (UTR) of the human DHFR gene transcript. 
They discovered C829T substitution located 223 base pairs downstream from the stop 
codon and positioned between the first and second polyadenylation site. This 
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polymorphism seems to influence DHFR expression, which increased with the number of 
T alleles being highest in TT individuals [39]. Consequently, the C829T-associated 
increase in DHFR expression may reduce MTX-related cytotoxicity. Indeed, reduction in 
sensitivity to MTX driven by this polymorphism was subsequently documented by 
Mishra et al., 2007 [40], who further elucidated the functional role of this variation. They 
showed that this SNP is located near the microRNA (miR)-24 3' UTR binding site and 
that it affects DHFR expression by interfering with miR-24 function. Analysis in vitro 
using Chinese hamster ovary derived cell lines that lack DHFR showed that the cells with 
the T allele bind miR-24 less efficiently, resulting in a 2-fold increase in DHFR mRNA 
half-life and, hence, higher DHFR mRNA and protein levels. This in turn affected 
sensitivity to MTX. The cells with the T allele were 4-fold more resistant to MTX as 
compared with cells without this allele [40]. It is known that miRNAs play an important 
role in different biological processes, such as cell proliferation, cell death, stress 
resistance and fat metabolism through the regulation of gene expression [41]. They may 
also be differentially expressed in human cancers or may act as oncogenes and tumor 
suppressors by targeting key regulators of cell growth [42, 43]. Moreover, translational 
control mediated by miRNAs plays an important role in the mechanism of cellular 
resistance to anti-cancer drug treatment [44]. The work by Mishra et al. [40, 45, 46] was 
the first to show that genetic polymorphisms may affect drug sensitivity acting through 
this mechanism. Several groups reported that C829T is non-polymorphic (or appears with 
very low minor allele frequency) in Caucasians [13, 20]. Nevertheless, it would be worth 
verifying whether this is also true at the transcriptional level and does not result from the 
difficulty in designing the primers for DNA amplification (i.e., pseudogenes and 
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repetitive elements). Changes in the level of DHFR expression and consequently in 
sensitivity to MTX can be also due to the genetic polymorphisms located in the promoter. 
The polymorphisms in the 2 kb region upstream of the first or minor transcription 
initiation site (corresponding to the minor DHFR promoter) were recently analyzed in a 
cohort of childhood ALL patients [23]. Association of individual polymorphisms and 
resulting haplotypes with ALL outcome revealed that a reduction in relapse-free survival 
was associated with A and C alleles located at positions 317 and 1610 upstream from a 
minor transcription initiation site, respectively. The association was also noted with the 
haplotype harboring these alleles, arbitrarily named haplotype *1. Haplotype *1 
conferred higher transcriptional activity, as shown by reporter gene assay and quantitative 
mRNA analysis, likely explaining a worse prognosis in patients carrying this haplotype. 
In addition to the minor promoter, the human DHFR gene also has a downstream major 
promoter [3, 4]. This adjacent regulatory region is located between minor and major 
transcript initiation sites and has been shown to act as a non-coding interfering transcript, 
controlling the transcription of productive mRNA from the major promoter [4]. The 
polymorphisms of this region were recently defined [24] and tagging variations were 
subsequently analyzed in the same group of ALL patients [24]. The haplotype analysis 
revealed diversification of haplotype *1 [23] into five subtypes, and only one of those, 
*1b, was responsible for the lower relapse-free survival observed in ALL patients, 
defining more precisely the relapse predisposing variations of DHFR. This association 
seems to be confined to patients with high-risk of relapse, as defined by classical clinical 
prognostic criteria, and it was further validated in an additional cohort of ALL patients. 
The *1b subtype was characterized by a particular allele combination defined by allele T 
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and A at positions 35 and 308 from the first transcription initiation site, respectively, 
compound length polymorphisms composed of 9bp insertion at position 63 and triple 9bp 
element at position 91. The 9bp repeat element of the compound length polymorphism 
was initially observed by Fujii et al. [47] and resembles that described in DHFR 5’UTR 
[19] and a mismatch repair gene (hMSH3) overlapping DHFR [48], although the 
sequence alignment and the number of repeats were to a certain extent differently 
resolved. Importantly, *1b was the only haplotype *1 subtype associated with higher 
mRNA levels and was predicted in silico to affect the structure of the major promoter 
[24]. It has been shown [3, 4] that the DHFR repression is regulated by a non-coding 
interfering transcript and that this regulation is due to the formation of a stable complex 
between noncoding RNA, which also acquires a different conformation, and the major 
promoter. It is, thus, possible that the *1b haplotype could affect the function of the non-
coding transcript, resulting in an observed increase in mRNA levels and a higher risk of 
ALL relapse [24]. Low-dose MTX is considered the ‘gold standard’ of therapy for 
rheumatoid arthritis (RA) patients [49]. Nevertheless, there is considerable inter-
individual variation in its clinical efficacy. A substantial number of patients do not 
respond to treatment, whereas others (10-30%) develop drug side effects requiring 
discontinuation of therapy [50, 51]. Wessels et al., 2006 [50], analyzed the association of 
genetic polymorphisms of the folate pathway with MTX efficacy, expressed as a disease 
activity score, and methotrexate toxicity, specifically respiratory, gastrointestinal, skin, 
mucosal and hepatic adverse drug events (Table 1). Among DHFR polymorphisms, 
they analyzed DHFR G-473A (rs1650697) replacement in 5’ UTR and DHFR A35289G 
(rs1232027) substitution positioned relative to the translation initiation site. No 
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association was found, whereas in contrast, Chandran et al. [52] found an association of 
the A allele of A35289G polymorphism with MTX efficacy in patients with psoriatic 
arthritis. The study conducted in RA patients from northern India [53] addressed 
additional DHFR A/T polymorphism in 3’UTR (position 1171 of mRNA, rs7387) and 
revealed its contribution to MTX efficacy only in a multivariate model when analyzed 
together with other variations of folate dependent enzymes. Regarding the potential 
functional role of DHFR polymorphisms selected for rheumatoid and psoriatic arthritis 
study, little can be said. The G-473A variation in 5’UTR (rs1650697) corresponds to 
C35T substitution (given relative to the forward strand and first transcription initiation 
site) described in ALL patient analysis [24]. Individually this polymorphism does not 
seem to have an impact on mRNA levels. However the T allele is one of the alleles of 
haplotype *1b, which, as described above [24], seems to increase DHFR expression. The 
polymorphism in 3’ UTR such as rs7387 [53] may potentially affect mRNA stability. 
However, it is not clear what the functional role [54] of the A35289G variation located 
several Kb downstream from the 3’UTR would be (based on dbSNP data [55]). Another 
polymorphism in LD with this DHFR variation may possibly explain the positive 
association reported. 
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CONCLUSION 
 
DHFR is a critical folate cycle enzyme targeted by antifolate medication used in the 
treatment of cancer and rheumatoid arthritis. The change in DHFR expression and 
activity caused by genetic polymorphisms may affect an individual’s predisposition to 
respond to the treatment in terms of efficacy and drug side effects. Due to the crucial role 
DHFR plays in the conversion of DHF to THF required for nucleic acid synthesis and 
methylation reaction, DHFR gene polymorphisms might affect diseases dependent on 
folate status, such as cancer and spina bifida. The genotype-phenotype relationships have 
only begun to unravel. The results obtained hold promise for the future. They are still 
scarce and sometimes contradictory requiring further analysis and replication. It is clear 
that other polymorphisms of the folate pathway, dietary intake and different genetic and 
epigenetic mechanisms beyond genetic polymorphisms may contribute toward the 
variability in treatment responses, the understanding of which would allow such 
information to be used in disease prevention and treatment tailored to individuals. 
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Table 1:  
Summary of the studies associating DHFR polymorphisms with disease susceptibility or 
response to treatment. 
 
Location/Position Polymorphism Impact Related Disorders Reference 
 
Intron 1 19-bp insertion /deletion 
Low-serum folate/ 
high homocysteine, 
change in mRNA 
levels 
NTD 
Breast cancer 
(13, 17) 
(21) 
Intron 3 A10372C A8890G  unknown Colon cancer (33) 
3'-UTR C829T 
Interfering with miR-
24 function, higher 
DHFR mRNA and 
protein levels 
MTX 
resistance (40) 
Minor promoter* C-1610G or T  A-317/G  
    Higher DHFR 
       expression 
Higher risk of 
relapse in ALL (23) 
Major promoter* 
G308A C35T  
Length 
polymorphism 
63/91: 9-bp 
insertion deletion/ 
9-bp repeat 
 
Higher DHFR 
expression 
Higher risk of 
relapse in ALL (24) 
Downstream to 3' 
UTR A35289G  Unknown 
MTX efficacy 
in patients with 
psoriatic 
arthritis 
(52) 
3'UTR A1171T Unknown 
MTX efficacy 
in patients with 
RA 
(53) 
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Table summarizes positive associations of DHFR polymorphisms with related disorders; 
DHFR, dihydrofolate reductase; MTX, methotrexate; ALL, acute lymphoblastic 
leukemia; RA, rheumatoid arthritis; NTD, neural tube defects; del, deletion. 
*polymorphism in the DHFR minor and major promoter defining *1 and *1b haplotype, 
respectively associated with higher DHFR expression and higher risk of relapse in ALL 
patients. Position of the polymorphism is given relative to the transcription or translation 
initiation site, or refers to the position within indicated intron. ** rs SNP number from 
dbSNP database at National Center for Biotechnology Information (NCBI) is provided as 
long it is available. 
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Key points:  
x Thymidylate synthase 3R/3R genotype in cells from ALL patients is predictive of 
methotrexate response in vivo in a dose-dependent fashion. 
x Increase in MTX dose may overcome MTX resistance associated with this 
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Abstract                            
Pharmacogenetics study conducted in children with acute lymphoblastic leukemia (ALL) 
showed that 3R/3R genotype of tandem repeat polymorphism in thymidylate synthase 
(TS) gene confers higher risk of relapse. Using xenogeneic mouse model, we investigated 
whether this genotype is associated with resistance to methotrexate (MTX). Response 
was estimated in mice injected with leukemia cells from two 3R/3R patients and two 
patients negative for this genotype. The response was dose-dependent: mice injected with 
patients’ cells with 3R/3R genotype were resistant to 0.25 and 1 mg/kg MTX doses, 
relative to mice injected with patients’ cells without this genotype; dose escalation to 
5mg/kg efficiently bypassed genotype-associated MTX resistance. Obtained results 
provide functional explanation for the significantly higher risk of relapse seen in 3R/3R 
ALL patients and suggest that these patients might benefit from an increase in MTX 
dose. Furthermore, xenogeneic mice model can serve as a preclinical tool to explore 
individualized treatment options. 
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Introduction 
The treatment of paediatric acute lymphoblastic leukemia (ALL) has greatly improved in 
the past four decades due to the introduction of effective combination risk-adapted 
therapies.1 Therapy resistance nevertheless remains a major obstacle to successful 
treatment2 due to unfavourable pharmacokinetics and pharmacodynamics or particular 
disease features.3 Several pharmacogenetics markers have been shown to contribute to 
this variability and to correlate with the risk of relapse in ALL (reviewed by Pui1 and 
Ansari4), including tandem repeat polymorphism in thymidylate synthase (TS) gene. ALL 
patients who are homozygous for high expression triple repeat (3R) allele5 had 
significantly higher risk of relapse,6-11 whereas low expression double repeat (2R) allele 
was associated with higher frequency of treatment-related toxicity.12-14 TS is inhibited by 
methotrexate (MTX) polyglutamates15 and the presence of TS 3R/3R may suggest a need 
for different doses and/or schedules in order to improve the treatment efficacy. However, 
the poly-chemotherapeutic combinations commonly used for ALL treatment do not allow 
the clear demonstration of a direct relationship between TS genotype and a resistance to 
MTX only. To address genotype-based treatment response we used xenogeneic mice 
models that are well suited for in vivo studies of human ALL16,17 since they retain the 
fundamental biological characteristics of the original disease such as leukemogeneicity, 
clonality and chemotherapy response.18-20 We investigated the effect of various MTX 
doses on leukemia development in mice injected with in vivo expanded pre-B ALL 
patient’s blasts harboring or not the relapse-predisposing TS 3R/3R genotype.  
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Methods 
Bone marrow aspirates were obtained from newly diagnosed paediatric ALL patients 
treated at the CHU Sainte-Justine in Montréal, Canada. DNA was extracted from bone 
marrow samples of ALL patients and genotyping was performed to define presence or 
absence of TS 3R/3R genotype. Genotyping was performed as described previously.5,6 
Bone marrow mononuclear cells (BMMC) samples were evaluated for phenotypic 
analysis of blasts content by flow cytometry. Patient’s blasts were injected intravenously 
into NSG mice (NOD/LtSz-scid IL-2Rgammanull). Mice were randomized to receive 
MTX at either 0.25; 1 or 5 mg/kg/day or PBS as described.18,21 Leukemia development 
was monitored by FACS staining in the peripheral blood. Details are provided in 
supplemental Methods. 
The study has been approved by the Institutional Ethical Review Board in 
Research of the CHU Sainte-Justine and an informed consent was obtained from the 
patients and/or their parents. All animal experimental procedures were approved by our 
Institutional Committee for Good Animal Practices in Research. 
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Results and discussion 
We analyzed two ALL patients with the TS 3R/3R genotype (TS positive, TS+) and two 
consecutive ALL patients without this genotype (TS negative, TS-), identified by 
genotyping as 2R/3R. None of the patients had the fusion gene transcripts that might have 
interfere with MTX efficacy,22 as shown by routine testing of the major chromosomal 
translocations. In all cases, the hCD45+ cells were confirmed to be leukemic blast 
because they harboured the same B-cell phenotype as in the primary leukemic cells from 
which they were expanded (Supplemental Table S1). Likewise, TS genotype remained 
the same throughout the experiments (Figure S1). 
We evaluated the efficacy of 3 MTX doses (0.25, 1.0 and 5.0 mg/kg) between 
mice injected with TS+ and TS- patients cells. The time-to-leukemia, the kinetics of 
development and the number of patient blasts found in mice peripheral blood, either 
expressed in percentage of human cells (Figure 1A) or in absolute counts/μL of leukemic 
cells (Figure 1B), differed from one patient to another in untreated mice (Figure 1). 
Despite these differences, the response pattern to MTX could be clearly delineated 
between TS+ and TS- patients with a resistance to MTX observed in the NSG mice 
injected with TS+ leukemia cells relative to mice injected with TS- cells (Figure 1). The 
results were concordant for patients with same genotype. Lower efficacy of MTX in mice 
injected with TS+ cells was observed for both 0.25 and 1 mg/kg MTX doses, with the 
differential effect of genotype being particularly apparent for the 1mg/kg dose. However, 
in all cases, high MTX dose (5 mg/kg) was efficient to maintain very low levels of 
circulating blasts. 
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In order to normalize the response to MTX for all patients regardless the kinetics 
of blasts development in mice, we assessed the relative efficacy of MTX treatment for 
each dose compared to the untreated (PBS) group by assuming that the mean levels of 
blasts in the PBS group corresponded to 0% of treatment efficacy, and that a complete 
absence of circulating blasts corresponded to a 100% efficacy (Figure 2). MTX efficacy 
at 0.25 and 1 mg/kg increased with time for the mice injected with blasts from TS- 
patients, whereas the MTX efficacy decreased with time for the mice injected with blasts 
from TS+ patients (P ranging from .01 to < .0005 by week +1 post MTX), strongly 
suggesting an absence of efficacy of MTX at these doses against TS+ cells. For the 5 
mg/kg MTX dose, the MTX efficacy was similar in mice injected with patients’ TS+ and 
TS- cells with somewhat lower efficacy in mice with TS+ cells, particularly from week+3 
to week+5. Importantly, in mice injected with TS+ cells, an obvious increase in MTX 
efficacy was seen when compared to lower doses (68% vs. 1-9%, P < .0001), illustrating 
that dose escalation can maintain low levels of leukemia in this genotype condition.  
Engraftment of human ALL cells in NSG mice has been extensively 
reported,16,19,23-25 however there is no evidence about the relevance of this xenogeneic 
model to investigate therapeutic implication of patient genotype and drug dose 
adjustment. Here, we demonstrate the relationship between the TS 3R/3R genotype and 
the resistance to MTX treatment in dose-dependent manner in this model. Dose-response 
curves and normalization of effect by calculating the relative efficacy of MTX as 
compared to PBS were useful to assess the efficacy of MTX among various specimens 
who may not have the same kinetics of proliferation, and to define the dose ranges where 
differential genotype effect is most apparent. Mice injected with blasts from TS+ ALL 
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patients were resistant to MTX dose of 0.25 and 1 mg/kg MTX and the resistance status 
was overcome by an increase in the dose. These results are in accordance with the 
association studies strongly supporting the possibility that ALL patients with higher risk 
of relapse due to TS 3R/3R genotype develop MTX resistance and might need higher 
doses for effective target inhibition. 
We also addressed how much the circulating murine cells could be affected by the 
chemotherapy and could therefore influence the MTX concentration caused by their 
metabolic uptake. The enumeration of murine CD45+ cells by flow cytometry showed no 
difference of the murine leukocytes of NSG mice in the blood (data not shown), 
suggesting that in this xenogeneic model of ALL, MTX at the doses that we used has an 
effect only on human cells and that the murine system does not interfere with the MTX 
effect.  
In conclusion, our data provide a functional demonstration that the blasts from 
patients with 3R/3R genotype are more resistant to MTX suggesting that the association 
observed in clinical setting was indeed due to genotype-driven resistance to MTX. 
Chemotherapy response in dose-dependent manner and through data normalization 
showed that this model could serve as a preclinical tool to explore individualized 
treatment options.  
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Figures legends 
 
Figure 1. Response to MTX in NSG mice injected with patients’ leukemia cells 
without and with TS 3R/3R genotype. (A) Percentage of human blasts among total 
lymphocytes in NSG mice injected with 5x106 pre-B ALL patient cells, treated with 
MTX or PBS. (B) Absolute counts of human blasts/μL of blood in NSG mice. Results are 
shown as mean ±SEM. n = 4-5 mice in each group. TS+ 1 and TS+ 2: TS positive 
patients with 3R3R genotype; TS- 1 and TS- 2: TS negative patients, without TS 3R3R 
genotype 
 
Figure 2. Efficacy of MTX treatment per dose. Efficacy of MTX (in %) is normalized 
as compared to the not treated groups (PBS), 0% efficacy corresponding to a level of 
blasts identical to the one observed in the corresponding group of PBS-treated mice and 
100% efficacy corresponding to undetectable blasts. TS- (full line) represent all mice 
injected with blasts of the 2 TS- ALL patients (n = 4-10 mice/week). TS+ (dotted line) 
represent all mice injected with blasts of the 2 TS+ patients (n = 3-10 mice/week). 
Results are showed as means ±SEM. Difference in efficacy is calculated by Mann-
Whitney two-tailed test at each time point. ns: not significant, *: P < .05; **: P < .005; 
***: P < .0005. Week 0 corresponds to the last value obtained prior to MTX treatment.  
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Supplemental Methods:  
Patient samples  
Bone marrow aspirates were obtained from newly diagnosed paediatric ALL patients treated 
at the CHU Sainte-Justine (Montréal, Canada). The patient’s samples were collected on 
heparinized tubes and bone marrow mononuclear cells (BMMC) were obtained after Ficoll-
Hypaque (GE Healthcare) density gradient centrifugation. BMMC were cryopreserved in 
DMSO 10% for later use. The study has been approved by the Institutional Ethical Review 
Board in Research of the CHU Sainte-Justine and an informed consent was obtained from the 
patients and/or their parents.  
Genotyping  
DNA was extracted from bone marrow samples of ALL patients and genotyping was 
performed as described previously.¹, ² In brief, the presence or absence of TS triple repeat, 
3R/3R genetic polymorphism was resolved by polymerase chain reaction (PCR) 
amplification. The primer sequences used for TS 3R/3R amplification were 5'-GTG GCT 
CCT GCG TTT CCC CC-3' and 5'-CCA AGC TTG GCT CCG AGC CGG CCA CAG GCA 
TGG CGC GG-3', for the forward and reverse primers, respectively. The PCR was performed 
for 3 min at 95°C followed by 40 cycles of 94°C for 30 s, 60°C for 30 s and 72°C for 1 min, 
completed by a final extension step at 72°C for 7 min. PCR amplification was followed on 
3% agarose gel electrophoresis at 85V for 1h30. 
Xenograft mouse model of human ALL and MTX chemotherapy  
NSG mice (NOD/LtSz-scid IL-2Rγc null, Jackson Laboratory) were bred and maintained 
under specific pathogen-free conditions in micro-isolator cages and provided with autoclaved 
food and water in the research animal facility of the CHU Sainte-Justine.  
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BMMC samples were thawed and evaluated for phenotypic analysis of blasts content by flow 
cytometry (see Methods below). Patient’s blasts were expanded in a primary round of in vivo 
expansion by injecting between 1 to 5 x106 thawed ALL patient blasts in the lateral tail vein 
of one to three non-irradiated NSG mice. In order to deplete the T lymphocytes present in the 
sample that may have caused a xeno-Graft-versus-Host Disease (GvHD) in the primary 
injection, mice received anti-CD3 antibody as previously described.³ Mice were evaluated for 
leukemia development by detection of circulating human blasts in the blood by flow 
cytometry (see Methods below). The mice were sacrificed when human blasts were ranging 
from 30-90% of total CD45 and/or CD19 and/or CD10-positive lymphocytes. The spleen was 
then crushed on a 70μm strainer using PBS. Human blasts were phenotyped and enumerated 
by flow cytometry. For the assessment of MTX sensitivity experiments, 7- to 10-week-old 
NSG mice were injected intravenously with 5 x106 in vivo expanded pre-B patient’s leukemic 
blasts with or without TS 3R/3R genotype. When the percentage of human ALL reached 1-
5% of CD45+ and/or CD19+ and/or CD10+ cells in peripheral blood, mice were randomized 
to receive MTX (Accord Healthcare) intra-peritonealy in groups of 5 individuals at either 
0.25; 1 or 5 mg/kg/day or PBS (negative control) on 4 consecutive days, every 14 days for a 
maximum of 8 weeks 4, 5 when possible. Peripheral blood was weekly collected from the 
saphenous vein on Microvette-200 heparinized tubes (Sarstedt). Red blood cells were lysed 
using ammonium chloride 0.3 M solution and cells were then analyzed by flow cytometry 
analysis. Mice were appropriately sacrificed at the end of MTX treatment or when they 
reached established limit points (hunch-back, weight loss and ruffled fur, assessed in blinded 
fashion as to assigned treatment). All animal experimental procedures were approved by our 
Institutional Committee for Good Animal Practices in Research.  
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Flow cytometry analysis  
Flow cytometry analyses of xenograft leukemia cells in peripheral blood and spleen were 
performed using monoclonal antibodies specific for murine CD45 conjugated with 
fluorescein isothiocyanate (FITC) (Ref. 553080), anti-human CD45 conjugated with 
allophycocyanin (APC) (Ref. 555485), anti-human CD19 conjugated with phycoerythrin 
(PE) (Ref. 555413), anti-human CD3 conjugated with BD Horizon V500 (Ref. 561416) 
(from BD Biosciences) and anti-human CD10 conjugated with phycoerythrin-cyanine7 (PE-
Cy7) (Ref. 312214) (from BioLegend) were used for enumeration in absolute counts or in 
proportions of human blasts in patient’s bone marrow and in mice peripheral blood and 
spleen. Dead cells were excluded by 7-amino actinomycin D (7-AAD) staining (BD 
Biosciences). Count Bright Beads (Life Technologies) were added in each tube for absolute 
counts determination. Flow cytometry analysis was performed using an LSRFortessa flow 
cytometer (BD Biosciences). The development of leukemia in mice was determined by 
enumeration of the proportion of human cells among total lymphocytes (human + murine) as 
previously described 4 and by the enumeration of absolute counts of blast cells. The results 
were analyzed using FCS Express 4 for Flow Cytometry RUO Edition (De Novo Software).  
Statistical analysis  
Results were analyzed using GraphPad Prism 4.0 (GraphPad Softwares Inc., La Jolla, USA) 
and are shown as mean ±SEM. Elsewhere, two-tailed Mann-Whitney tests were used with 
significance set at P ≤ .05.  
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Supplemental Table 
 
 
 
Table S1: Patient samples characteristics. Bone marrow aspirates were obtained from pediatric 
pre-B ALL patients. Phenotype of pre-B ALL blasts were determined by flow cytometry using 
monoclonal antibodies and DNA was extracted for evaluation of the presence or absence of the TS 
3R/3R genetic variant. Primary blasts were also frozen and thawed for in vivo expansion in NSG 
mice. BM: bone marrow, M: male.  
 
Patient Classification Source Age 
(years) 
Sex Clinical status Blasts (%) Phenotype 
TS negative 1 
(TS-1) 
Pre-B ALL BM 4 M Diagnosis 92 CD45 CD19 
CD10 
TS negative 2 
(TS-2) 
Pre-B ALL BM 7 M Relapse 81 CD45 CD19 
CD10 
TS positive 1 
(TS+1) 
Pre-B ALL BM 4 M Diagnosis 97 CD45 CD19 
CD10 
TS positive 2 
(TS+2) 
Pre-B ALL BM 3 M Diagnosis 73 CD19 CD10 
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Supplemental Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
              
 
Figure S1: TS genotypes before and after leukemic cell engraftment in NSG mice. TS-1 
and TS-2: Samples from 2 ALL patients without TS 3R/3R genotype; TS+1 and TS+2: 
Samples from 2 ALL patients with 3R/3R genotype. Samples from each patient are obtained 
at 3 points, prior to engraftment (P) and following first (1) and second (2) engraftment in 
mice. Ctrl: Genotype controls for 2R/2R, 2R/3R and 3R/3R. 
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Statement of translational relevance 
Acute lymphoblastic leukemia (ALL) is the most frequent malignancy of childhood. The 
treatment of pediatric ALL has greatly improved in the past four decades due to the 
introduction of effective combination risk-adapted therapies. However, therapy resistance 
in a significant number of children is still a major obstacle to successful treatment. 
Intensive treatment has also significant short-term side effects and long-term 
consequences. Identification of genetic component underlying this variability, would 
allow traditional treatment to be complemented by genotype-based drug dose adjustment. 
Asparaginase is a critical component of ALL treatment. We recently analyzed genes of 
asparaginase action pathway in relation to the risk of relapse in ALL. Here we 
investigated whether the same genes may affect asparaginase-related toxicities and found 
that particular polymorphisms and haplotypes in asparagine synthetase gene may affect 
these adverse reactions in ALL patients. The study provides a new insight into the 
pharmacogenetics of asparaginase-related treatment complications in ALL. 
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Abstract 
Purpose. Asparaginase is a standard and critical component in the therapy of childhood 
acute lymphoblastic leukemia (ALL), but it is also associated with several toxicities.  
Experimental design. We recently reported the results of an association study between 
asparaginase pathway genes and event free survival (EFS) in childhood ALL patients. 
The same polymorphisms were interrogated here in relation to allergies, pancreatitis and 
thrombotic events following treatment with E.coli asparaginase.  
Results. Among patients of discovery group, allergies and pancreatitis were more 
frequent in individuals who are homozygous for the triple repeat allele (3R) of asparagine 
synthetase (ASNS) gene, resulting in remarkably higher risk of these toxicities associated 
with 3R3R genotype (OR for allergies =14.6, 95% CI= 3.6-58.7, p<0.0005 and OR for 
pancreatitis = 8.6,  95% CI= 2.0-37.3, p=0.01). In contrast, the ASNS haplotype *1 
harbouring double repeat (2R) allele had protective effect against these adverse reactions 
(p≤0.01). The same haplotype was previously reported to confer reduction in EFS. The 
risk effect of 3R3R genotype was not replicated in validation cohort, whereas the 
protective effect of haplotype *1 against allergies was maintained (p≤0.002). Analysis 
with additional polymorphisms in ASNS locus in CEU cell lines showed that haplotype 
*1 is diversified in several subtypes  of which one was associated with reduced in vitro 
sensitivity to asparaginase (rs10486009, p=0.01) possibly explaining an association seen 
in clinical setting.  
Conclusions. This finding might have implication for treatment individualization in ALL 
and other cancers employing asparagine depletion strategies. 
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Introduction 
Over the past four decades, treatment of childhood acute lymphoblastic leukemia (ALL) 
has improved importantly such that ~ 80-85% of patients are cured with current therapy 
regimen. Up to 20% of patients experience treatment failure whereas treatment-related 
toxicities are often life-threatening and are the primary cause of interruption or 
discontinuation of chemotherapy. Asparaginase (ASNase) is a standard component in the 
childhood ALL treatment (1). It is required by all cells for survival and is normally 
produced by the enzyme asparagine synthetase (ASNS). Malignant lymphoblasts are 
thought to have low ASNS levels and thus depend on extracellular sources of asparagine 
for their rapid growth. Depletion of asparagine by ASNase selectively kills leukemia cells 
by decreasing protein biosynthesis (2). Associations between success of ALL treatment 
and ASNase dose intensity or formulation have been reported in several clinical studies 
(3-5). E.coli derived enzymes are more potent, are associated with higher efficacy, but 
also with higher toxicity (5-7). Side effects related to ASNase treatment include allergic 
reactions that occur in 20–40% patients and require change of drug formulation. Two 
most serious and most frequent dose-limiting asparaginase-related toxicities are 
pancreatitis and thrombotic events reported in up to 18% and 5% of ALL patients, 
respectively (8, 9). Pancreatitis usually develops after the first few doses of asparaginase 
suggesting that it may occur as a result of an underlying predisposition rather than as a 
cumulative drug effect (9).  
We recently analyzed relationship between event free survival (EFS) in childhood 
ALL patients and genes in ASNase pathway (10), which were differentially expressed 
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between asparaginase resistant and sensitive cells (11-13).  We showed that promoter 
variant of transcriptional factor ATF5 involved in ASNS regulation, is associated with 
higher promoter activity and confers higher risk of ALL relapse in patients who received 
E.coli ASNase (10).  Association with lower EFS has been also found with tandem repeat 
(14) in ASNS gene and with resulting haplotype (arbitrarily named haplotype*1) (10). 
Here we report the analysis of the same set of polymorphisms in ASNS, ATF5 and ASS1 
(arginosuccinate synthase 1) in relation to ASNase-related acute complications (allergies, 
pancreatitis and thrombotic events) in two independent childhood ALL cohorts. 
 
Patients and methods 
Study population and endpoints in the analysis 
The study population consisted of 285 Caucasian children (98% of French-Canadian 
origin) diagnosed with ALL at the Hospital Sainte-Justine, (HSJ, Montreal, Quebec, Qc, 
Canada)  between January 1989 and July 2005 (QcALL cohort or test group) who 
received E.coli asparaginase as a part of Dana-Farber Cancer Institute ALL Consortium 
protocols DFCI 87-01, 91-01, 95-01 or 00-01 (Table 1) (5, 6, 10, 15). Details of 
asparaginase administration across these treatment protocols are described elsewhere (10, 
16). The information on asparaginase-related toxicity was assessed by retrospective chart 
review. Pancreatitis was defined as an elevation in the serum amylase level >3 times 
normal associated with clinical signs and symptoms consistent with the diagnosis (9). 
Pancreatitis cases were classified by duration of symptoms as severe or mild/moderate 
(16). Hypersensitivity reactions to asparaginase were characterized by local 
manifestations at the injection site as well as systemic manifestations (erythema, 
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swelling, urticaria, rash, pruritus, tachypnea, and wheezing) (17). Thrombosis was 
identified by clinical symptoms and confirmed by radiological imaging based on 
institutional guidelines (18). 
Previously obtained genotypes in asparaginase pathway genes were used for the analysis, 
as described in Rousseau et al (10), including 8, 2 and 4 SNPs in ATF5, ASNS and ASS1 
genes, respectively (Supplemental Table 1). The estimates of linkage disequilibrium 
(LD), and haplotype phase was obtained by PHASE software, version 2.0 (19). 
Association of genotypes/haplotypes with presence of each ASNase related toxicity was 
assessed by chi-square test. Adjustment for multiple testing (including all polymorphisms 
and all toxicities analyzed) was estimated by false discovery rate (FDR) (10). For 
significant associations, genotypes/haplotypes were grouped in two categories and the 
genotype-associated risk was expressed as odds ratio (OR) with 95% confidence interval 
(CI). Analyses of haplotypes within significantly associated gene were not further 
corrected. 
A validation set of Caucasian patients called the Dana-Farber Cancer Institute (DFCI) 
group was composed of a 248 patients who received E.coli ASNase within  DFCI 95-01 
and 00-01 ALL treatment protocol in remaining (without HSJ) consortium institutions (5, 
6, 16).  Baseline characteristics did not significantly differ from discovery group (Table 
1).  
Cellular proliferation assay 
In vitro sensitivity to asparaginase was assessed in lymphoblastoid cell lines (LCLs) from 
89 individuals of Northern and Western Europe (CEU), as described by Chen et al. (17) 
The drug concentration resulting in 50% inhibition of cell growth (IC50) during 48h 
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incubations time was estimated using several E.coli asparaginase concentrations ranging 
from 0.01-10 IU and the GraphPad software by fitting sigmoid dose-response curves. 
Obtained values were correlated to genotypes using Mann-Whitney or Kruskal-Wallis 
test. 
Informed consents were obtained from parents or guardians before enrolment into the 
study. The study was approved by institution ethics committees. 
 
Results  
 
Allergies, pancreatitis and thrombotic events occurred in discovery group (QcALL) with 
the frequency of 15.8%, 5.6% and 3.5%, respectively.  Pancreatitis was in most cases 
severe (in 13 out of 16 cases) and systemic allergies also occurred more frequently (in 37 
out of 45 subjects with allergic reactions). Analysis between these toxicities and SNPs in 
ASNS, ATF5 and ASS1 genes revealed an association of tandem repeat polymorphism 
(rs3832526) in ASNS gene with both pancreatitis and allergies (p=0.008 and p<0.0005, 
respectively, Figure 1A). These complications were more frequent among patients that 
were homozygous for the triple repeat allele (3R) resulting in 8-14 fold risk elevation 
(OR for allergies =14.6, 95% CI= 3.6-58.7, and OR for pancreatitis = 8.6, 95% CI= 2.0-
37.3).  The association with allergy remained significant with FDR of lower than 1%, 
whereas association with pancreatitis remained significant only with FDR of 16%.  We 
further analyzed ASNS haplotypes composed of the tandem repeat polymorphism and 
promoter C-181T substitution (rs3757676). Two haplotypes were associated with 
allergies and pancreatitis; Homozygosity for haplotype *2, uniquely tagged by 3R allele 
conferred higher risk of these toxicities (high sensitivity haplotype), whereas haplotype 
*1 defined by C-181 and 2R alleles had protective effect (low-sensitivity haplotype, OR 
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for allergies =0.4, 95% CI= 0.2-0.8, and OR for pancreatitis = 0.2, 95% CI= 0.07-0.7, 
p≤0.01, Figure 1B). In our previous analysis the low-sensitivity haplotype *1 conferred 
reduction in EFS in QcALL cohort (10). We further performed the analyses of ASNS 
gene in replication (DFCI) cohort. Pancreatitis and allergies occurred in this group with 
the frequency of 8.5% and 23%, similar to the frequencies reported for the 00-01 clinical 
trial (16). Distribution of severe/moderate pancreatitis and systemic/local allergies 
differed from discovery group, 33.3% pancreatic cases had moderate form and among 
patients with allergies, 50.1% had local manifestation. The risk effect of 3R3R genotype 
(or haplotype *2) was not seen, whereas protective effect of haplotype *1 against 
allergies was maintained, particularly against local allergic manifestation and in patients 
assigned to high risk group (p=0.002 and p<0.0005, respectively, Figure 1B).  
To further understand the variability of ASNS gene, we retrieved  an information on all 
SNPs in coding and regulatory regions with minor allele frequency higher than 5%, that 
might have been identified (20) since our first analysis of this gene (10).  We also 
included SNPs within 5kb upstream and downstream from gene boundaries.  Sixteen 
additional tag SNPs were analyzed, which were all except one (Val210Glu) located 
beyond the coding region (Figure 2A). Given high number of resulting haplotypes and 
low frequency of adverse events, detailed stratified analysis would have limited power in 
patients. We analyzed instead whether polymorphisms defining particular haplotype 
subtypes might have functional role as estimated by in vitro sensitivity assay in 
lymphoblastoid CEU cell lines. The protective *1 haplotype was diversified in 5 subtypes 
(defined by SNPs at 5 different positions, Figure 2B). Two polymorphisms (rs10486009 
and rs6971012, positions 4 and 5 in Figure 2B) correlated with in vitro sensitivity to 
 130 
 
ASNase, (p=0.01 and p=0.002, respectively, Figure 2C). The TT genotype of rs6971012 
had lower sensitivity, which was further reduced by the G allele of rs10486009 (Figure 
2C, p=0.001) suggesting that it may contribute to protective effect of haplotype *1 
observed in clinical setting.  In contrast, only one haplotype defined by 3R allele 
remained after addition of other ASNS polymorphisms and it did not affect in vitro 
sensitivity to ASNase. 
 
Discussion 
 
Differences in susceptibility to asparaginase have been attributed to variable 
levels of ASNS expression in number of studies: ASNS levels in leukemia cell lines, 
patients lymphoblasts and surrounding mesenchyme cells suggested that elevated ASNS 
levels may counteract the ASNase effect and underlie the resistance to treatment (11, 21, 
22). Lower ASNS expression might then be expected to mediate higher sensitivity to 
treatment and possibly higher frequency of ASNase-related complications. We found that 
the 3R3R genotype of tandem repeat polymorphism correlated more frequently with 
pancreatitis and allergies in discovery group. Tandem repeat polymorphism is located in 
intron 1, but upstream from translation initiation site and was reported to act as an 
enhancer element (14). The 3R allele increased ASNS promoter activity in embryonic 
kidney cell line (14). We did not observe relationship between 3R3R genotype with 
mRNA level (10) or in this study with in vitro sensitivity to ASNase. The effect of 3R 
allele on therapeutic responses to ASNase is also ambiguous. Recent study reported that 
3R allele can affect early response to ALL treatment, as defined by the number of 
leukemic blasts following one ASNase dose (23). We did not find an association of 3R3R 
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genotype with reduced EFS (10) and in this study we did not replicate an association of 
3R3R genotype with adverse reactions of ASNase. Other polymorphisms/haplotypes in 
ASNS gene cannot explain this discrepancy; there was only one haplotype defined by 3R 
allele when additional polymorphisms were included in the analysis. The differences can 
nevertheless be due to low frequency of 3R3R genotype, different distribution of 
severe/moderate and systemic/local allergies, or different geographical origin of 
discovery and replication group. Other genes beyond those studied here, as well as 
disease and treatment characteristics might also play a role.  For example, it has been 
shown that leukemic cells carrying TEL/AML1 fusion gene are more sensitive to 
treatment with ASNase compared to other subtypes of ALL (24); several polymorphisms 
of aspartate metabolic pathway have been associated with ASNase sensitivity in vitro  
using ALL cells and LCL cell lines (25); top ranking SNPs for ASNase -related allergies 
have been identified in the gene coding for glutamate receptor in genome-wide 
association study (17). Distribution of treatment protocols differed between discovery and 
replication group (Table 1) and patients might have received different ASNase doses, 
however association with pancreatitis and allergies with 3R3R genotype was maintained 
in the discovery group when analysis was limited to patients treated with DFCI 95-01 and 
00-01 protocols (p ≤ 0.02, not shown). Further and larger studies are needed to confirm 
the role of 3R3R genotype and to explore whether this finding is applicable to other 
populations. 
The results obtained for haplotype *1, harbouring 2R allele, seems more 
consistent and correlated with lower frequency of allergies in both discovery and 
replication patient cohort. This is in agreement with previously reported association of 
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the same haplotype with reduced EFS (10), suggesting its lower sensitivity in response to 
ASNase treatment. Analysis of additional polymorphisms in ASNS locus revealed 
diversification or haplotype *1 in several subtypes; one of them (defined by minor allele 
of rs10486009) seems particularly interesting because it was associated with reduced 
sensitivity to ASNase in vitro, possibly explaining lower sensitivity of haplotype *1 seen 
in clinical setting. Our finding might be as well of interest for the treatment of other 
cancers since asparagine depletion strategies using ASNS inhibitors and asparaginase 
have been suggested in pancreatic and ovarian malignancies (26, 27). Tumor specific up-
regulation of ASNS was also reported in castration-resistant prostate cancer and 
correlated with the progression to a therapy-resistant disease state (28).  
In conclusion, we reported an association of 3R3R genotype of ASNS gene with a 
higher frequency of ASNase–related adverse reactions. The association was not seen in 
the replication group suggesting limited study power or possible modulating role of other 
genes and/or disease and treatment characteristics or different patient origin. Haplotype 
harboring 2R allele seems to have protective role against ASNase allergies in both 
discovery and replication patient set. Extension of the analysis to additional 
polymorphisms and cellular proliferation assay in response to ASNase treatment, 
identified variants possibly explaining lower sensitivity of this haplotype observed in 
clinical setting.  
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Table  1. Characteristic of ALL patients in the test (QcALL) and validation (DFCI) 
cohort 
 
 No of subjects and frequency (%) 
Characteristic QcALL (n=285) DFCI (n=248) 
Sex     
Female 130 (45.6) 114 (46.0) 
Male 155 ( 54.4) 134 (54.0) 
Age, y     
<10 224 (78.6) 203 (81.9) 
≥10 61 (21.4) 45 (18.1) 
WBC, ×109/L    
<50 242 (84.9) 202 (81.5) 
>50 43 (15.1) 46 (18.5) 
Cell type    
B 267 (93.6) 227 (91.5) 
T 18 (6.4) 21 (8.5) 
Risk groups    
Standard 137 (48.1) 153 (61.7) 
High 148 (51.9) 95 (38.3) 
Treatment protocol    
87-01 20 (7.0)   
91-01 57 (20.0)   
95-01 92 (32.3) 73 (29.4) 
2000-01 116 (40.7) 175 (70.6) 
 
Protocol distribution is different between QcALL and DFCI group (p=0.001), whereas 
the remaining characteristics do not differ significantly. WBC, white blood cell count.  
 138 
 
Figure Legend 
Figure 1. Asparaginase-related acute complications in childhood ALL in relation to 
tandem repeat polymorphism and resulting haplotypes in asparaginase synthase 
(ASNS) gene  
A. Tandem repeat polymorphism in relation to allergies and pancreatitis in ALL 
patients of discovery cohort. The frequency of individuals with genotypes of 
tandem repeat polymorphism in patients with (+, dark gray bars) and without (–, 
light gray bars) allergies and pancreatitis (left and right side panel, respectively). 
Numbers of individuals represented by each bar, p value and risk associated with 
3R3R genotype (odds ratio, OR, with 95% confidence interval, CI) are indicated 
on each plot. 
B. Risk of allergies and pancreatitis in relation to ASNS haplotypes. Linear 
display of risk (OR with 95% CI) associated with haplotype *1 and *2 in 
discovery (QcALL) and replication group (DFCI) based on C-189T substitution 
(rs3757676) and tandem repeat polymorphism (rs3832526). Protective effect of 
haplotype *1 in DFCI group was more apparent against local allergies (LA) and 
in high risk (HR) group. Sequence and frequency of 3 major haplotypes are 
indicated in the box on the right-bottom side. 
Figure 2.  ASNS polymorphisms, haplotype *1 sub-classification and cellular 
proliferation assay  
A. Linear display of SNPs in ASNS locus. Linear display refers to all SNPs with minor 
allele frequency (MAF) > 5% located in coding regions and within upstream and 
downstream gene boundaries of ~5kb. Exonic and coding sequences are represented by 
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open and gray boxes, respectively, and SNPs are represented by gray dots. Rs number 
and MAF are indicated next to each polymorphism. The black and gray arrows indicate 
the transcription and translation start site, respectively, estimated according to reference 
sequence NM_183356.3. Polymorphisms analyzed in patients are indicated in bold 
character. Arrows next to the polymorphisms indicate those depicted in Figure 2B. 
B. Haplotype *1 subtypes. Diversification of ASNS haplotype *1 on several subtypes, 
based on the identified polymorphic positions (positions 1 to 5 indicated by respective rs 
numbers). Haplotype resolution is performed using all SNPs presented in Figure 2A; only 
those that are relevant for haplotype *1 diversification are presented. 
C. In vitro sensitivity to asparaginase in relation to rs6971012 and rs10486009. Box 
plots representing ASNase IC50 in CEU lymphoblastoid cell lines with and without C 
allele of rs6971012, with and without G allele of rs10486009 and with combined 
rs6971012 and rs10486009 genotypes (G+, C+ or none of these alleles, (CG)-) are 
presented in left, right and middle panel, respectively. The number of individuals 
represented by each bar and the p value obtained by Mann-Whitney or Kruskal-Wallis 
test is indicated on the plot. 
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Figure 1. 
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Figure 2. 
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Supplemental Table 1. Polymorphisms in ATF5, ASNS and ASS1 genes analyzed in 
the relation to ASNase related complications 
 
Polymorphisms 
gene dbSNP position variation 
ATF5 rs3826777 -1072 G/A 
 rs1273686 -670 A/C 
 rs1152232 -34 A/G 
 rs2241702 321 A/T 
 rs11554772 1562 C/T 
 rs283525 3288 C/T (Leu83) 
 rs283526 3403 T/C (Pro121Leu) 
 rs8667 3911 G/A 
ASNS rs3757676 -181 T/C (-strand) 
 rs3832526 232 
2R/3R ou 4R (-strand) 
R : 
CCTGCGCCCCG(C/T)GC 
ASS1 rs928518 -1343 G/T 
 rs11244367 -621 G/T 
 rs2071367 34 G/T 
 rs10901072 26133 C/T (His167) 
 
 
Ancestral allele is given in bold and minor allele is underlined. The polymorphisms is 
presented as a change from ancestral to derived allele, unless ancestral allele is not 
known, when the change is given from major to minor allele. SNPs in coding region 
leading or not to amino-acid substitutions are indicated. SNP position is given respective 
to transcription initiation site which is estimated for ATF5, ASNS and ASS1 based on 
respective mRNA sequencesNM_012068, NM_001673 and NM_00005. 
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Supplemental Table 2.Identity of polymorphisms genotyped only in controls 
 
Polymorphisms 
gene dbSNP position variation 
ATF5 rs36220131 -1919 G/T 
 rs36220132 -1867 T/C 
 rs4402677 -1150 T/G 
 rs36220128 -1112 G/A 
 rs36220125 -731 G/A 
 rs36220126 -705 C/T 
 rs4802639 -581 T/C 
 rs4802640 -514 C/T 
 rs35018314 -270 C/A 
 rs11083991 -162 G/A 
 rs1152231 -9 A/G 
 rs892027 1276 G/T 
ASNS rs11554430 144 T/C(-strand) 
 rs1803163 20238 
G/T (Pro547His)         
(-strand) 
ASS1 rs7043097 -1790 A/C 
 rs4740430 -1636 C/T 
 rs11244364 -1357 G/A 
 rs12352216 -706 A/G 
 rs7854616 -456 A/T 
 rs35269064 13843 G/T 
 rs10121464 56450 T/C 
    
 
SNPs genotyped only in controls and excluded from the analysis in ALL patients either 
because of low frequency or LD with other SNPs. dbSNPnumber is provided.Ancestral 
allele is given in bold and minor allele is underlined. The polymorphisms is presented as 
a change from ancestral to derived allele, unless ancestral allele is not known, when the 
change is given from major to minor allele. SNPs in coding region leading to amino-acid 
substitutions are indicated. SNP position is given respective to transcription initiation site 
which is estimated for ATF5, ASNS and ASS1 based on respective mRNA sequences 
NM_012068, NM_001673 and NM_00005 and reference32 for ATF5. 
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Supplemental Table 3. In silico prediction of transcription factor binding sites 
affected by ATF5 polymorphisms  
 
 
 
 
The gain or loss of transcription factor binding sites (TFBS) induced by minor allele 
(MA) of SNPs (including genotyped polymorphisms and polymorphisms in correlation) 
defining 5 (*1-*5) ATF5 haplotypes, as obtained by Matinspector-Genomatix software, 
version 2.1 (http://www.genomatix.de). Ancestral allele is given in bold and minor allele 
is underlined. 
 
 
Polymorphisms    
Identity dbSNP MinorAllele  MA Gained TFBS  
G-1072A rs3826777  A  SOX/SRY-sex/testis determining and related HMG box factors  
A-670C rs1273686  C  
Fork head domain factors, 
Grainyhead-like transcription 
factors, Cellular and viral myb-like 
transcriptional regulators 
 
C-514T rs4802640  T  
Twist subfamily of class B bHLH 
transcription factors, TALE 
homeodomain class recognizing TG 
motifs 
 
C-270A rs35018314 A  
Cart-1 (cartilage homeoprotein 1), 
Lim homeodomain factors, GATA 
binding factors 
 
A-34G rs1152232   G  Vertebrate TATA binding protein factor  
A321T rs2241702    T  NA  
G1276T rs892027    T  NA  
C1562T rs11554772 T  MEF3 binding sites  
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                                          Unpublished results 
 
 
A. In vitro approach 
B. In vivo xenograft mouse model of human ALL 
The results assessing in vivo approach using xenograft mouse model are presented in the 
article 2. Here are presented only the results of in vitro approach. 
 
1. MTX targets genes, DHFR and TS: 
 
For in vitro assay 93 CEPH cell lines were tested. Results of cell viability test against 
MTX indicate that 42.6% of cell lines are sensitive, 23.4% are resistant to MTX 
treatment, whereas remaining had intermediate phenotype. In our experiment IC50 
threshold for sensitive, intermediate and resistant status were <0.01, 0.01-0.1 and >0.1 
µM respectively. Genotyping analysis showed that 9 (9.67%) carried DHFR *1b 
haplotype, 26 (27.95%) had 3R3R TS genotype, 3 (3.22%) had combination of these 
genotypes and the remaining had no at risk genotypes. Association analysis between 
sensitivity status of LCLs and these genotypes revealed absence of association (Table 1). 
No association was seen if IC50 distribution was analyzed across genotype groups 
(DHFR *1b haplotype, P= 0.6 and 3R3R TS genotype, P= 0.2). 
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Table 1: Association analysis between sensitivity status of LCLs and DHFR *1b 
haplotype and 3R3R TS genotype. 
 
 
 
 
Gene genotype   
Sensitivity 
status   P 
            
DHFR *1b haplotype Sensitive Intermediate Resistant   
  0 36 (94.74%) 29 (82.86%) 19 (95%) 0.4 
  1 2 (5.26%) 6 (17.14%) 1 (5%)   
            
TS 3R/3R         
  0 26 (66.67%) 25 (17.43%) 16 (84.21%) 0.4 
  1 13 (33.33%) 10 (28.57%) 3 (15.79%)   
            
 
 
 
2. ASNase pathway genes: 
 
 
In vitro sensitivity test on 93 LCLs against E.coli ASNase indicates that 60.21% of cell 
lines were sensitive (IC50<0.3 IU), 13.98% were resistant (IC50>0.4 IU) to E.coli 
ASNase treatment and remaining cell lines had intermediate phenotype (Figure 1). The 
results assessing in vitro sensitivity to ASNase and ASNS polymorphisms are presented in 
the article 3. Here are presented only the results on ATF5. Genotyping analysis of ATF5 
T1562C variation showed that 83 (93.25%) carried CC, 5 (5.61%) had CT and 1 cell line 
had TT genotype. Based on our experiment in lymphoblastoid cell lines in response to 
Ecoli ASNase, we did not find an association between ATF5 T1562C variation and 
sensitivity to ASNase, as determined by IC50 values (P= 0.2) (Table 2).  
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Figure 1: Frequency of sensitive, resistant and intermediate LCLs against E.coli 
ASNase. 
 
 
Table 2: Results of association of IC50 distribution across ATF5 T1562C variation. 
 
Gene   
Sensitivity 
status   P 
          
ATF5 T1562C Sensitive Intermediate Resistant   
          
CC 52 (92.86%) 23 (95.83%) 12 (92.30%) 0.9 
          
CT 3 (5.36%) 1 (4.17%) 1 (7.7%)   
          
TT 1 (1.78%) 0 0   
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Importance of pharmacogenomics approaches for childhood ALL 
leukemia:  
 
The treatment of paediatric ALL has greatly improved due to the introduction of effective 
combination risk-adapted therapies. However, therapy resistance is still a major obstacle 
to successful treatment, whereas intensive treatment has also important short-term side 
effects and long-term consequences. Unfavourable clinical pharmacokinetics and 
pharmacodynamics as well as cellular drug resistance play a major role in ALL treatment 
failure [8, 9]. Candidate gene analysis and GWAS are two fundamental approaches that 
improved pharmacogenetic knowledge and gave an insight into the specific drug 
metabolism and signalling pathways in paediatric ALL [10]. Identification of 
polymorphisms modulating treatment response may lead to different treatment schedules, 
improving the efficacy of treatment and allowing for a reduction in drug side effects. 
Individualizing MTX and ASNase dose based on pharmacogenetic markers in childhood 
ALL patients, may lead to better cure rate compared with standard doses of these drugs 
[11]. Several steps are needed prior to the translation of pharmacogenetic marker to 
clinical practices. These include replication through an independent association studies, 
functional significance of identified polymorphisms, which is prerequisite for subsequent 
dose adjustment, and finally prospective clinical where the effect of genotype-based 
treatment adjustment is analyzed. The step of functional validation in ALL is complex, 
since childhood ALL treatment protocols include several chemotherapeutic agents. 
Findings in clinical setting reflect usually an association of a given polymorphisms with 
overall response to treatment, therefore an evaluation in the context of individual drug of 
these protocols is crucial for understanding the impact of pharmacogenetics markers [12]. 
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 ALL as a model of cancer disease: 
ALL is the most frequent malignancy of childhood and a principal cause of cancer-
related mortality in children due to a persistent group of patients that does not respond to 
standard treatment [8, 13, 14]. Pharmacogenetics approaches can help understanding 
genetic basis of relapse in ALL. Childhood ALL treatment protocols include 
chemotherapeutics which are generally given at doses near those that lead to severe 
toxicity. Thus, individualized therapy may reduce toxic episodes in susceptible patients 
[10]. Well known clinical symptoms and biological profile of ALL facilitate 
identification of genetic component influencing therapeutic responses [11]. 
Polymorphism in drug metabolising enzymes and targets, have been shown to affect drug 
pharmacokinetic and pharmacodynamic pathway in childhood ALL [11, 12]. However, 
despite increasing information obtained through pharmacogenetic studies, only 
polymorphisms in thiopurine methyltransferase (TPMT), an enzyme that catalyses S-
methylation of mercaptopurine and thioguanine, have been  introduced in clinical practice 
[15, 16] suggesting that much work still remains to facilitate transition to clinical 
implementation. 
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Lymphoblastoid cell lines (LCLs) and their utility: 
 
The LCLs are Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines derived 
from B-lymphocytes. LCLs are promising model system to study the genetics of drug 
response and are useful tool for identifying polymorphisms related to drug sensitivity, 
including the sensitivity to anticancer agents. Importantly many data are publicly 
available for hundreds of established LCLs such as genome-wide genotype and gene 
expression data as well as data derived from next-generation sequencing (DNA and 
RNA-Seq) [17, 18]. Centre d’Étude du Polymorphism Humain (CEPH) families, 
International HapMap Project and Human Variation Panel are three main collections of 
LCLs established from healthy individuals of different origin. As a complement to 
clinical studies, LCLs can be used to investigate associations between genetic variation 
and chemotherapeutic susceptibility. Several cellular phenotypes can be measured to 
determine cellular sensitivity to a drug, including cytotoxicity, apoptosis, gene expression 
changes and intracellular concentration of the drug or metabolite. In several 
pharmacogenomics studies LCL model have been used to identify genes and variants that 
predict drug response and toxicity [18].  Genome-wide analysis has been successfully 
used to identify novel genetic variants predicting sensitivity to a variety of 
chemotherapeutics, including etoposide, cisplatin, carboplatin, daunorubicin, cytarabine 
and ASNase [19][93, 94]. Because of adverse side effects of anti-cancer drugs, there are 
no healthy volunteers for genetic studies. Likewise, due to narrow therapeutic index of 
many anticancer drugs, small change of dosage can be associated with extensive toxic 
response and in some cases could be fatal. Thus, challenge to study drug toxicity is one of 
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advantages of using LCLs in pharmacogenomics studies [18]. In addition, availability of 
different data sets allows overlaying them on the top of each other investigating at the 
same time genetic influences on gene expression and cellular phenotypes. LCLs offer the 
opportunity to test the finding via experimental manipulation and therefore begin to get at 
the underlying biology. LCLs are an unlimited resource and allow for the evaluation of 
toxic drugs in a controlled testing system [94].There is nevertheless several disadvantages 
of working with LCLs for pharmacogenomics discovery. They are representing one cell 
type and the phenotype observed from in vitro experiments may not be recapitulated in 
vivo. Experiments with LCLs are also subject to in vitro confounders, such as Epstein-
Barr virus (EBV) that can infects B-lymphocytes in vitro and affects the gene expression 
patterns of LCLs [21], growth rate differences between cell lines, and thaw effects. A 
disadvantage that is especially important to take into consideration for pharmacogenomic 
studies is that most LCLs lack expression of many CYP450 enzymes and several 
transporters; therefore, they are most useful for identifying the contribution of 
pharmacodynamics genes [94]. In spite of these limitations, LCL-based systems have 
been so far proven useful in advancing the field of pharmacogenomics. 
In this project we used 93 CEU LCLs to access the role of particular variation in DHFR, 
TS, ASNS and ATF5 genes with in vitro sensitivity to ANSase and MTX.  
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 Xenograft mouse model of ALL: 
The xenograft mouse model gradually provides a stable, reproducible and clinically 
relevant model, used to study different malignancies and diseases [22, 23], including 
bone marrow mesenchymal stem cells transplantation and ALL [24, 25]. Two extremely 
immunodeficient mouse lines, the nonobese diabetic severe combined immune deficient 
(NOD/SCID) strain and NOD/LtSz-scid IL-2Rγc null (NSG) mouse have been 
developed, which can be humanized very effectively [25-27]. Lack of T, B, and NK cells 
in NSG mice due to a deficient common cytokine receptor g-chain, result in defective 
cytokine signalling of IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 [23, 28]. NSG mice 
bearing additional mutation on IL-2 receptor gamma chain (IL2ry) gene, lead to severe 
defect in natural killer (NK) cells [29, 30]. In a case of engraftment of leukemia cells in 
mice, the immune system of NSG mice can not reject injected cells and their immune 
system will have no influence on the outcome of leukemia, because of lack- of mature T, 
B and NK cells [23, 31, 32]. The recipient NSG mice will show the same 
clinicopathologic pattern and type of leukemia as seen in donor patients. Accordingly 
mice retain the fundamental biological characteristics of the original disease [22, 31-33]. 
Although leukemia cells developed in both NOD/SCID and NSG mice strains, NSG mice 
demonstrate superior engraftment of human cord blood, adult CD34+ hematopoietic stem 
cells and multilineage differentiation when compared with NOD/SCID [23, 25, 29]. 
Diamanti et al compared the engraftment of childhood T-ALL and B-cell precursor ALL 
cells in NSG and NOD/SCID strains as well as the phenotype and functional ability of 
cells capable of engrafting these mice. They concluded that engraftment of unsorted 
leukemia cells was 1.2 to 7.7-fold higher in NSG mice than in NOD/SCID mice, 
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regardless of subtype or risk stratification group [25]. Likewise, Agliano et al (2008) also 
demonstrated that human acute leukemia cells engraftment in NSG mice was 
accompanied with faster development of leukemia related symptoms and higher 
percentage of leukemia cells in blood, marrow and spleen of NSG mice [34].  The NSG 
strain is a more permissive host for engraftment of paediatric leukemia [25].  NSG mice 
showed higher engraftment levels, shorter length of time to engraftment, earlier presence 
of leukemia cells from blood and bone marrow compared to NOD/SCID strain [25, 28, 
29].  Xenograft mouse model has been used for engraftment of patient’s leukemia cells 
and expansion of leukemia cells in NSG mice, has been shown by several groups [25, 27, 
34-36]. Importantly, the recent study by Woiterski provided an evidence for a validity of 
such model to constitute a surrogate marker for clinical parameters. They performed an 
analysis in primary and serial engraftment using 54 primary paediatric B-ALL, myeloid 
leukemia (AML) and T-ALL samples. They characterized the leukemogenic profile and 
correlated engraftment kinetics with clinical outcome. PCR-based minimal residual 
disease marker expression and fluorescence in situ hybridization confirmed the presence 
of patient-specific genetic aberrations in mice. Analysis of genes known to be important 
in the leukemogenesis of all three diseases revealed that well-known tumor-regulating 
genes were expressed to a comparable extent in mice and men. Overall survival of NSG 
mice highly correlated with the individual prognosis of B-ALL, AML and T-ALL 
patients. These studies suggest that in vivo model provides a valuable preclinical tool to 
explore the heterogeneity of leukemic disease and exploit patient-tailored leukemia-
targeting strategies [27].  This model has been also used to explore apoptosis in leukemia 
cells [37], cytotoxic effects of cord blood cytokine-induced killer (CB-CIK) cells or 
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interleukin (IL)-27 against human B-ALL [38]. Other haematological malignancies, such 
as AML were investigated with these models as well demonstrating disease recapitulation 
and self-renewal capacity [35].  
 
Importance of polymorphisms in DHFR gene: 
The antileukemia effect of methotrexate involves the inhibition of DHFR [2]. DHFR 
plays a critical role in the conversion of DHF to THF that are required for nucleic acid 
synthesis and methylation reaction [39].The change in DHFR expression and activity 
caused by genetic polymorphisms may thus affect an individual predisposition to respond 
to the treatment in terms of efficacy and drug side effects. Recent pharmacogenetic 
studies in our lab showed an association of DHFR promoter polymorphisms with lower 
event-free survival and inferior ALL outcome. The polymorphisms might have affected 
the function of the non-coding transcript involved in DHFR expression regulation [2, 3]. 
Indeed, particular haplotype (named*1b, defined by particular allelic combination 
derived from six polymorphic site in the major and minor promoter of DHFR) increased 
mRNA levels possibly explaining an association with a higher risk of ALL relapse seen 
in the clinical setting [3].  In my research project I attempted to get further insight into the 
effect of DHFR polymorphism on MTX sensitivity using cellular proliferation assay. 
DHFR genotypes assessment carried on in 93 CEU LCLs identified DHFR *1b haplotype 
with similar frequency as obtained in ALL patients; 9 (9.67%) cell lines carried this 
haplotype. Analysis with an in vitro sensitivity to MTX in LCLs did not reveal significant 
association. Several attempts have been made to establish the role of DHFR expression in 
MTX resistance in childhood ALL and other diseases such as rheumatoid or psoriatic 
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arthritis. Matherly and coworkers (1995), have been shown that, DHFR overexpression is 
associated with resistant to MTX in childhood ALL patients [40]. Likewise, Goker and 
coworkers (1995) demonstrated that DHFR gene overexpression may be a significant 
cause of acquired MTX resistance in ALL patients with p53 gene mutations, which may 
lead to defective cell cycle control [41]. Based on estimation in 40 newly diagnosed 
patients with ALL, there was a correlation between unfavorable EFS and DHFR 
expression [42]. Matheson et al (2007) also reported low level amplification of DHFR in 
ALL patients both at presentation and relapse [43]. One of the polymorphisms studied by 
several groups is insertion/deletion (indel) of 19pb sequence in the first intron of DHFR 
gene. Ongaro et al, 2009 demonstrated that, deletion allele was associated with an 
increased risk of hepatotoxicity in adult ALL [44], whereas association of homozygosity 
for the insertion allele with thrombocytopenia in childhood ALL was reported by Salazar 
et al, 2012 [45]. Ongaro et al, (2009) and Vagace et al, (2011) reported that 
homozygosity for DHFR 19 bp deleted allele has been associated with increased 
hepatotoxicity in leukemia patients treated with MTX [44, 46]. In contrast, Dulucq et al, 
(2008) did not find such an association [2]. They identified linkage disequilibrium (LD) 
of 19bp indel with the promoter polymorphisms; several haplotypes carried either 19-bp 
ins or 19-bp del allele [2], which might explain some discrepancy observed among 
studies. Polymorphisms in DHFR gene have been investigated in other diseases treated 
with MTX. Some studies found an association of the polymorphism located several Kb 
downstream from the 3’UTR in patients with psoriatic and rheumatoid arthritis [39, 47, 
48]. 
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Importance of polymorphisms in TS gene:  
TS plays a critical role in maintaining a balanced supply of deoxynucleotides required for 
DNA synthesis. Due to its major role in cell proliferation TS is a target of several 
chemotherapeutics including MTX. Change in TS expression in ALL patients has been 
reported [49, 50].  Our group conducted an association studies in ALL patients treated 
with MTX, and demonstrated that patients who are homozygotes for high activity TS 3R 
genotype had a reduced event-free survival (EFS) [51]. The similar observations were 
made by others. Rocha et al (2005) reported that TS 3R3R genotype was associated with a 
higher risk of hematologic relapse [52]. Similarly, Sepe et al (2012) found an association 
of TS 3R4R genotype and poor prognosis in ALL [53]. In contrast, the low activity 2R 
allele correlated with increased toxicity in ALL patients treated with MTX including 
more frequent osteonecrosis and stomatitis [54, 55]. TS polymorphism seems also to 
influence susceptibility to ALL. High expression 3R allele could limit DNA damage in 
rapidly dividing tissues that have greater requirement for DNA. Indeed, several studies 
showed as association of 3R allele with a reduced risk of leukemia suggesting potential 
protective role against childhood ALL development [56, 57].   
We addressed the effect of TS polymorphisms on MTX sensitivity using in vitro and in 
vivo approach. Analysis of cellular proliferation assay in relationship to 3R3R genotype 
did not reveal significant association, whereas experiments conducted in mice seem to 
recapitulate well observation seen in clinical setting. Although engraftment of human 
ALL cells in NSG mice has been shown by us and others [25, 34-36], there was no 
evidence about the relevance of this model to investigate therapeutic implication of 
patient genotype and drug dose adjustment. We showed the relationship between the TS 
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3R/3R genotype and the resistance to MTX treatment in dose-dependent manner. Mice 
injected with blasts from TS+ ALL patients (with 3R3R genotype) were resistant to MTX 
dose of 0.25 and 1 mg/kg MTX, relative to mice injected with patients’ cells without this 
genotype (TS-) that responded well to the dose of 1mg/kg. Importantly, genotype-related 
resistance was bypassed by an increase in the MTX dose. Our results are in accordance 
with association studies in patients with childhood ALL showing relationship between 
3R3R TS genotype and  higher risk of relapse [51] strongly supporting the possibility that 
higher risk of relapse in TS 3R/3R patients is due to MTX resistance. These patients 
might need higher MTX doses for effective target inhibition. In order to define minimal 
increase in MTX dose that can overcome resistance related to TS 3R/3R genotype, we 
performed additional experiments in mice injected with blasts from TS+ ALL patients 
using MTX doses of 1, 1.5 and 2 mg/kg.  Based on these results, the suppression of 
leukemia cell proliferation was initiated in NSG mice that were treated with dose of 2 
mg/kg (Figure 1, unpublished results). The resistance status can be thus reversed with the 
doubling MTX dose, which might be of importance for intensification and maintenance 
phase of treatment of 3R3R positive ALL patients. Given that our association study did 
not detect a correlation between 3R3R genotype and higher risk of toxicity [58], increase 
in MTX dose might be justified, and prospective study with the dose adjustment 
according to the genotype could be considered as well. Some factors might influence our 
in vivo experiments in mice, such as environment and characteristics of mice. The 
environment within a mouse model is different from that in human leukemia; therefore, 
populations that form leukemia in mice may differ from those that contribute to disease 
progression in the patients [25]. Similarly, characteristics of mice, like for example 
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different sex of NSG, might influence the engraftment [27, 59, 60].  Our experiments 
included analysis in several patients and compared relative difference in MTX response 
between several mice injected with leukemia cells with and without TS 3R3R genotype 
(five mice each), minimizing the impact of mice environment. The analysis carried at 
different point of experiments revealed that leukemia cells expanded in mice retain the 
same B cell phenotype and same TS genotype as in patients they originated from. To 
further address whether the significant differences observed, are MTX specific, we plan 
to test response of mice with the same TS genetic background to other drugs used in ALL 
treatment, like for example vincristine, which does not employ same action pathway.   
There are several reasons for the discrepancy seen between in vitro and in vivo model. 
There is a significant difference in MTX exposure between these models. In in vitro 
approach, cell lines are continuously exposed to MTX, whereas in in vivo models, the 
MTX is undergoing pharmacokinetic and dynamic changes, which more similarly reflect 
changes in patients [22]. In regard to other TS polymorphisms a G to C substitution was 
described in the second repeat of 3R allele that may further modulate TS expression [1, 
61]. C allele seems to abolish the binding site for upstream regulatory factor resulting in 
different pattern of TS expression that has been proposed based on this additional 
polymorphism: high (3RG3RG), median (3RG3RC and 2R3RG) and low TS expression 
profile (2R2R, 2R3RC and 3RC3RC) [61, 62]. Our group has studied the effect of 
substitution in 3RG allele on ALL outcome [1]. Although the 3RG3RG individuals had 
lowest EFS, this reduction was not significantly different compared to other 3R3R 
subgroups [1]. And finally, an association of TS 28bp repeat polymorphisms with other 
malignancies and diseases was reported in several studies. Increased risk of colorectal 
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cancer among TS 3R/3R individuals [63]; and association of 3R3R genotype with poor 
prognosis in breast and gastric cancer was reported. Colorectal cancer patients with TS 
3R3R genotype who were treated with 5-FU, presented a poor prognosis [64-67]. Similar 
was noted in rheumatoid patients (RA) treated with MTX. Kumagai et al (2003), 
demonstrated that RA patients who are homozygous for the 3R allele require higher dose 
of MTX compared to those with 2R allele [68].  
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Figure 1: MTX increase dose to overcome resistance in NSG mice injected with 
blasts from TS+ ALL patients:  Additional experiments with different doses (1, 1.5 and 
2 mg/kg). The suppression of leukemia cell proliferation starts in NSG mice injected with 
blasts from TS+ ALL patients, treated with 2 mg/kg MTX. 
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ASNase-related polymorphisms in childhood ALL and personalized 
ASNase therapy: 
ASNase is a critical component of ALL treatment whose anti-leukaemia effect is related 
to asparagine depletion. Differences in susceptibility to asparaginase correlated to 
variable levels of ASNS expression in different studies. Increase of ASNS level in 
leukemia cell lines, patient’s lymphoblasts and surrounding mesenchyme cells have been 
reported [69-72]. The increase in ASNS levels can counteract the ASNase effect leading 
to subsequent resistance to ALL treatment, whereas lower ASNS expression can mediate 
higher sensitivity to treatment leading to higher frequency of ASNase-related 
complications [5]. Some studies conducted in clinical setting reported that an elevation of 
ASNS expression was predictive of inferior disease outcome [4].  Stams et al found that 
ASNase-resistant, TEL-AML1–negative B cells which are usually associated with inferior 
prognosis, had significantly higher ASNS expression compared with TEL-AML1-positive 
B-lineage ALL [73]. There are nevertheless other studies which did not find an 
association between an expression of ASNS and response to ASNase [74]. Interesting 
observation has been made by Iwamoto et al who have shown that BM-derived 
mesenchymal cells express much higher levels of ASNS compared with leukemic 
lymphoblasts and may mediate resistance to ASNase [69]. Wing, et al contradicted this 
finding by reporting absence of ASNS association with an increase of asparagine level in 
bone marrow of patients [70]. Our lab focused on the polymorphisms in ASNase action 
pathway, particularly on the genes that were shown by microarray profiling as 
differentially expressed between ASNase sensitive and resistant cells [71, 72, 75-78]. 
Association of these polymorphisms with event free survival (EFS) in childhood ALL 
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patients revealed event predisposing role of several genetic variations, particularly 
tandem-repeat ASNS polymorphism and T1562C variation in ATF5 gene, transcription 
ASNS regulator [4].  Based on these results, the T1562 variation was associated with 
reduced EFS in ALL in both the test and the replication cohorts, and was limited to 
patients who received Escherichia coli asparaginase which might be related to higher 
asparaginase activity. Indeed, E coli asparaginase treatment has been shown to have 
higher efficacy and toxicity compared with Erwinia-ASNase [4]. ATF5, as a 
transcriptional activator of ASNS, binds to the nutrient-sensing response unit of the ASNS 
gene and activate ASNS transcription after nutrition deprivation [79]. ATF5 C1562T is 
located in the regulatory 5’UTR region and may affect promoter activity and mRNA 
levels or translation ATF5 efficiency, which is regulated by alternatively spliced 5'UTR α 
and β [80]. Our analysis indicated that ATF5 T1562 allele confers higher ATF5 promoter 
activity. Mechanism behind this association could have been proposed: more important 
asparagine depletion caused by E.coli ASNase leads to higher ATF5 up-regulation which 
is further potentiated in individuals with high-activity allele, such as T1562, leading to 
resistance to ASNase [4]. Our experiment in lymphoblastoid cell lines in response to 
ASNase treatment meant to establish this mechanistic relationship. However no 
association between ATF5 T1562C variation and sensitivity to ASNase, as determined by 
IC50 values, was found which might be due to the number of reasons: discrepancy 
between in vitro and in vivo finding, concomitant role of other medications administered 
or contribution of surrounding mesenchymal cells in clinical setting. 
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Considering ASNS gene variations, tandem repeat polymorphism with most frequent 
double (2R) and triple repeat (3R) alleles was also associated with lower EFS.  
Particularly, haplotype harbouring 2R allele (arbitrarily named haplotype *1) was 
associated with reduction in EFS [4]. Our analysis of polymorphisms in ASNase pathway 
with ASNase-related complications revealed also the implication of tandem repeat 
polymorphism. Patients who were homozygous for 3R allele was more susceptible to 
pancreatitis and allergies [5], whereas carriers of haplotype *1 had lower frequency of 
these complications. This is in accordance with results of Rousseau et al (2011) which 
demonstrated the association of the same haplotype with reduced EFS, suggesting all 
together lower sensitivity of this haplotype in response to ASNase treatment [4, 5].  
Further analysis of additional polymorphisms in ASNS gene revealed diversification of 
haplotype *1 in 5 subtypes; two polymorphisms (rs10486009 and rs6971012,) defining 
particular haplotype subtypes correlated with in vitro sensitivity to ASNase. ASNase 
sensitivity in vitro seems to be driven by minor allele of rs10486009 possibly providing 
mechanistic explanation for lower sensitivity of haplotype *1, observed in clinical 
setting. In contrast, only one haplotype defined by 3R allele remained after addition of 
other ASNS polymorphisms and it did not affect in vitro sensitivity to ASNase. Akagi et 
al (2009) demonstrated that the tandem repeat sequences in ASNS gene functions as a 
transcriptional element. They have shown by luciferase reporter assay performed in 
embryonic kidney cell lines, that the number of tandem repeats increase promoter activity 
[81]. In accordance with this, Pastorrczak et al (2014) showed worse response in 3R3R 
ALL patients, particularly in early phases of treatment protocol following one ASNase 
dose [82]. Our finding does not support these observations, since 3R3R genotype was 
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rather associated with higher sensitivity to treatment. We did not notice an association of 
this genotype with mRNA levels [4] or in vitro sensitivity to ASNase [5]. It is possible 
that the DNA copy number alteration is not causing ASNS up-regulation in all tumours, 
and it might be that other mechanisms are involved in ASNS overexpression as well [83]. 
For example, it has been shown that high ASNS levels in TEL/AML1 [+] patients 
correlate with better prognosis compared to other subtypes of ALL [84]. Mechanism of 
mutant p53-mediated oncogenesis has been demonstrated by several studies [83, 85]. P53 
mutants with the gain of function properties, can bind to the ASNS promoter and induce 
ASNS expression [83, 85]. Increased prevalence of mutated p53 in advanced castration-
resistant prostate cancer (CRPC) and its association with ASNS overexpression was 
reported by Sircar and coworkers (2012) [83]. It would be possible that this mechanism 
plays a role in childhood ALL leukemia patients as well. Another mechanism of ASNS 
overexpression could be associated with the relative glucose and asparagine amino acid 
deficiency which exists in metabolically active advanced tumours. The glucose and 
asparagine amino acid deficiency in advanced tumours such as CRPC might as well lead 
to ASNS up-regulation [83]. To overcome ASNS overexpression due to glucose and 
asparagine amino acid deficiency, using ASNS inhibitors paired with ASNase, would be 
potent strategy in many tumours. In another study related to asparaginase 
hypersensitivity, Chen et al (2010) identified through genome-wide interrogation an 
association of genetic variations in the GRIA1 (glutamate receptor, ionotropic, AMPA 1) 
on chromosome 5q33 with risk of asparaginase allergy in ALL patients [86]. 
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Perspective of personalized therapy in ALL: 
MTX is an antifolate drug that acts through inhibition of DHFR and TS interrupting 
folate homeostasis. MTX was introduced as antileukemic drug about 60 years ago and 
still remains an important component of ALL treatment protocols. In spite of a number 
studies that evidenced the influence of genetic polymorphisms of folate metabolizing 
enzymes on MTX response [2, 3, 51], pharmacogenetic tests to predict the outcome of 
MTX treatment are not yet available. There are several reasons for the lack of 
personalized MTX treatment:  
1. The large number of observations was limited to single center cohorts, without 
replication sets.  
2. Small numbers of patients due to disease prevalence and long duration of ALL 
treatment protocol may reduce power of study increasing possibility of false positive 
associations. 
3. Considering that MTX exerts its action via folate pathway, these effects could be 
changed by patient’s folate level. Accordingly there are no evidences considering 
patient’s folate level through pharmacogenetic study on ALL. 
4. ALL treatment protocols are composed of multiple drugs with overlapping toxicities 
leading to difficulties in assigning these complications to MTX (or to one particular 
drug).  
5. Different populational background of patients enrolled in studies could increase chance 
of bias and make difficult comparison of results between studies. 
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6. Different dose of MTX and administration schedule among studies due to different 
ALL treatment protocol could modulate an association between polymorphisms and 
treatment outcome limiting the reproducibility of studies.  
7. Given complex pathway of MTX action few SNPs are not sufficient to explain MTX-
related resistance and adverse effects. Other variants in the same gene and epistatic 
interactions with other genes should be considered and analyzed. 
8. The association between polymorphism of folate metabolizing enzymes and MTX 
responses may be affected by other genes and their variations such as those involved in 
DNA repair or apoptosis. Most of pharmacogenetic studies focused only on 
polymorphisms of the folate metabolizing enzymes, which may increase false positive 
results [87]. Similar conclusion can be made for ASNase pharmacogenomics. Several 
other strategies may assist further pharmacogenetic studies such as i) understanding the 
mechanism of drug resistance through molecular profiles of leukemia cells in order to 
identify genes which affect sensitivity to ALL drugs [10, 87]. ii) Increase a number of 
studies that analyze an association with the MRD status, which was shown by many 
studies to help identifying patients who are at increased risk of relapse or death. iii) 
Pharmacogenomics studies with large sample sizes and replication cohorts are necessary 
to create stability and consistency in quantifying association between genotype and drug 
response [87-89]. iv) Pharmacogenetic models should include both genetic and clinical 
factors which can together better predict the disease outcome. v) Improve our 
understanding on the functionality of genetics variants. vi) Conduct studies which will 
monitor drug efficacy/toxicity in relation to polymorphisms in prospective manner. vii) 
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Genome-wide association studies approach may offer an alternative and unbiased 
approach conditional on the availability of large cohorts [87].  
Impact of ALL pharmacogenomics:  
In spite of extensive investigation regarding pharmacogenomics biomarkers, the potential 
and utility of pharmacogenomics in clinics, especially in case of ALL has be lowered 
than expected [90, 91]. Most of predictions may come true, but many years later than 
expected. Among all market chemotherapeutics, only 1-2% has pharmacogenomic-based 
recommendations. Among drugs used in childhood ALL protocol treatment only 6-MP, 
has a recommendation for TPMT genetic test which can help individualized therapy 
adapting initial doses based on TPMT genotypes [90-92]. For the other components of 
ALL treatment protocols, the data are not sufficiently consistent or, are only emerging to 
allow specific recommendations [91]. Many of them await replication, including 
applicability to different treatment protocols and different populations [10]. 
 In order to identify genetic component of treatment response combination of mutations 
in several genes, is more helpful than single gene approach, especially in case of drugs 
with complex intracellular pathway [46, 91]. The scenario of ALL pharmacogenetics is 
still complex and requires further research to identify whole array of genetic factors 
involved in drug efficacy and toxicity in childhood ALL patients. This will ultimately 
lead to precise risk stratification and personalized medicine by translating and integrating 
molecular tools into clinical practice. Some other important factors such as identification 
of leukemia specific genetic profile (somatic mutations), cytogenetics of leukemia cells, 
gene expression studies and minimal residual disease investigation can shed a light on the 
road of ALL pharmacogenomics research. 
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Limitations: 
The results of this thesis need to be considered in the context of several potential limitations. 
First, there was limited number of patients whose leukemic cells were available for 
engraftment in mice, for which reason we could not investigate by in vivo model the 
effect of DHFR and combined TS and DHFR genotypes. Although xenotransplantation 
model following engraftment of acute lymphoblastic leukemia cells with thymidylate 
synthase gene polymorphisms in NSG mice was successful, there are nevertheless several 
limitations. For example due to limited access for NSG mice of different sex, we used 
both female and male mice in the same experiment. Based on recent evidence, sex 
associated factors may play a role in growth and proliferation of engrafted leukemic cells 
in mouse model [27, 59, 60], although the data are not consistent. Some studies showed 
that engraftments is faster in male recipient compared to female mouse model [27, 59] 
whereas others showed that, female mouse model has instead faster engraftment [60].  
Considering LCLs, in spite of advantages of their use in pharmacogenomics studies, there 
are also drawbacks, these include difference in drug-induced effects due to cell type or 
the influence of non-genetic factors such as baseline growth rates, EBV copy numbers 
and ATP levels which may affects drug-induced phenotypes in LCLs [17, 18]. Other cells 
models also used in pharmacogenetic studies are fibroblasts and peripheral blood 
mononuclear cells; nevertheless they have no extensive genetic information available like 
LCLs [18]. Therefore illustrating the complexity of drug effects in the human body 
requires more than a single-model system. 
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Conclusions: In conclusion, this project provided an explanation for the mechanism 
behind association of TS and ASNS genotypes with therapeutic response in ALL. 
Although both in vitro and in vivo approach used in this thesis have their own inherent 
limitations, they have been shown useful to i) understand how variability in ASNS gene 
modulate sensitivity to ASNase treatment and ii) to confirm through in vivo model the TS 
genotype-driven resistance to MTX.  This may have an implication for genotype-based 
drug dose adjustment in order to decrease risk of relapse and drug-related toxicity in 
patients undergoing ALL treatment. Further work is needed to get an insight into the role 
of DFHR and ATF5 variations. Similar mouse model as one described for TS should be 
evaluated to define how these polymorphisms modulate sensitivity to MTX and ASNase. 
Chemotherapy response in dose-dependent manner and through data normalization 
showed by our NSG mice experiments suggested that this model can serve as a 
preclinical tool to explore individualized treatment options. The knowledge acquired 
through this work, can be useful for optimal treatment selection or tailoring therapy based 
on individual genetics in childhood ALL, but is also important for other haematological 
malignancies, using MTX and ASNase for treatment. Likewise, this model will allow 
validation of the variants in the genes controlling the action of other drugs used in ALL 
treatment that are or will be detected through pharmacogenetics studies of ALL. Finally, 
by anticipating that pharmacogenomics approaches and technology continue to improve, 
molecular genetic profiles associated with drug sensitivity in both ALL patients and their 
leukemia cells, will ultimately lead to better risk stratification of patients and 
individualized therapies, resulting in better health outcomes for children with ALL. 
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